Presentations in this session:

TUPEB084 Abstract	"Lipodystrophy" is not what it used to be: data from the Swiss HIV cohort study Presented by Alain Nguyen, Switzerland (TBC) Nguyen A.1, Bernasconi E.2, Battegay M.3, Opravil M.4, Evison J.-M.5, Tarr P.E.6, Schmid P.7, Perneger T.8, Hirschel B.9, Swiss Hiv Cohort Study 1University Hospital Geneva, Infectious Disease Service / HIV unit, Geneva, Switzerland, 2Hospital Lugano, Infectious Disease Service, Lugano, Switzerland, 3University Hospital Basel, Division of Infectious Diseases, Basel, Switzerland, 4University Hospital Zurich, Division of Infectious Diseases, Zurich, Switzerland, 5University Hospital Bern, Infectious Disease Service, Bern, Switzerland, 6University Hospital Lausanne, Infectious Disease Service, Lausanne, Switzerland, 7Hospital St-Gall, Infectious disease unit, St-Gall, Switzerland, 8University Hospital Geneva, Quality of Care Service, Geneva, Switzerland, 9University Hospital Geneva, Infectious disease / HIV unit, Geneva, Switzerland
TUPEA042 Abstract	A binary neutralizing determinant of gp120 defined by nucleophilic monoclonal antibodies Presented by Yasuhiro Nishiyama, United States (TBC) Nishiyama Y.1, Planque S.1, Mitsuda Y.1, Taguchi H.1, Jin L.1, Boivin S.1, Salas M.2, Hanson C.2, Paul S.1 1University of Texas-Houston Medical School, Chemical Immunology Research Center, Department of Pathology and Laboratory Medicine, Houston, Texas, United States, 2California Department of Health Services, Viral and Rickettsial Disease Lab, Richmond, California, United States
TUPEB095 Abstract	A Decade of HAART: effect on hospital admissions for HIV and AIDS in Brazil Presented by Cledy Eliana dos Santos, Brazil dos Santos C.E.1, Silveira O.1, Scapini R.1, Sakita K.1, Malheiros E.1, Barreira D.1, Serafim J.A.2, Ramos Filho C.F.3 1Ministry of Health, National STD/AIDS Program, Brasilia, Brazil, 2Ministry of Health, DATASUS, Brasília, Brazil, 3Federal University of Rio de Janeiro, Dept. Preventive Medicine, Rio de Janeiro, Brazil
TUPEA003 Abstract	A Feasibility study for detection of HIV specific cytotoxic T lymphocytes using rAAV delivery system Presented by B.J. Zheng, Hong Kong (TBC) Zheng B.J.1, Lee S.S.2, Wong K.H.2, Chan K.C.W.2, Chan C.S.1, Yuen K.Y.1 1The University of Hong Kong, Microbiology, Hong Kong, Hong Kong, 2Department of Health, Integrated Treatment Centre, Hong Kong, Hong Kong
TUPEB068 Abstract	A large prospective cohort study of cardiovascular risk and associated metabolic changes in HIV infection: CREATE 1 (cardiovascular risk evaluation and antiretroviral therapy) Presented by Michael Aboud, United Kingdom (TBC) Aboud M.1, Elgalib A.1, Pomeroy L.1, Kulasegaram R.1, Wierzbicki A.1, Larbalastier N.1, Makia F.1, Rahman S.1, Fiona L.2, Panayiotakopoulos G.3, Skopelitis E.3, Sharp A.3, Dimian C.4, Peters B.3, Cardiovascular Risk Evaluation And Antiretroviral ThErapy (CREATE) Team 1Guy's and St Thomas' Hospitals NHS Trust, Harrison Wing, London, United Kingdom, 2Department of Population Sciences, Royal Free site of UCL, London, United Kingdom, 3Academic unit of HIV and STDs, St Thomas' site of King's College London, London, United Kingdom, 4Department of GUM, Beckenham Hospital, Beckenham, Kent., Kent, United Kingdom
TUPEA082 Abstract	A new target for HIV vaccine: the critical role of an NKp44 ligand in the CD4+ T depletion by NK cells in SHIV162P3 infected macaques Presented by Patrice Debre, France (TBC) Vieillard V.1, Le Grand R.2, Debre P.1 1INSERM U543, Hôpital Pitié-Salpêtrière, Paris, France, 2CEA, Fontenay-aux-roses, France
TUPEC011 Abstract	A randomized controlled trial in Tanzania to assess the impact of HSV-2 suppressive therapy on genital HIV viral load among HSV-2 and HIV-1 seropositive women Presented by Clare Tanton, United Kingdom (TBC) Tanton C.1, Watson-Jones D.2, Rusizoka M.2, Le Goff J.3, Weiss H.1, Lefebvre C.3, Mugeye K.2, Baisley K.4, Changalucha J.4, Belec L.3, Everett D.4, Clayton T.1, Hayes R.1 1London School of Hygiene & Tropical Medicine, London, United Kingdom, 2African Medical & Research Foundation, Mwanza, Tanzania, United Republic of, 3INSERM U743 & Universite Paris V, Paris, France, 4National Institute for Medical Research, Mwanza, Tanzania, United Republic of
TUPEB008 Abstract	A randomized controlled trial of computer counseling to administer rapid HIV test consent and counseling in a public emergency department: final results Presented by Ann Kurth, United States (TBC) Kurth A.1, Spielberg F.2, Severynen A.1, Holt D.3 1University of Washington, School of Nursing: Biobehavioral Nursing & Health Systems, Seattle, United States, 2Formerly with University of Washington, Center for AIDS & STDs, Seattle, United States, 3University of Washington, Harborview Medical Center, Seattle, United States
TUPEA024 Abstract	Accumulation of escape mutants by Pol283-8-specific cytotoxic T lymphocytes in 2 different HLA class I restriction Presented by Yuichi Yagita, Japan (TBC) Yagita Y.1, Kawashima Y.1, Ariumi Y.1, Fujiwara M.1, Oka S.2, Takiguchi M.1 1Division of Viral Immunology, Center for AIDS Research, Kumamoto University, Kumamoto, Japan, 2AIDS Clinical Center, International Medical Center of Japan, Tokyo, Japan
TUPEC008 Abstract	Addressing microbicide trial disruption due to low HIV incidence: report of a community dialogue Presented by Morenike Ukpong, Nigeria (TBC) Ukpong M.1 1Nigeria HIV Vaccine and Microbicide Advocacy Group, Lagos, Nigeria
TUPEB121 Abstract	Age-related standards for CD4+ T-lymphocytes in healthy non-infected infants born to HIV-1 infected mothers from AMATA study in Rwanda Presented by Gilles François Ndayisaba, Rwanda Patrick N.C.1, Ndayisaba G.F.1, Rutanga C.1, Havuga E.1, Dhont N.1, Omes C.1, Peltier A.C.1 1Lux Development, Project ESTHER/AMATA, Kigali, Rwanda
TUPEB034 Abstract	Allele specific PCR for K103N detects mutations that are missed by consensus sequence genotype analysis and cases of transmission of 103N HIV in South Australia Presented by Jillian Maree Carr, Australia (TBC) Carr J.M.1, Green T.1, Shaw D.2, Hart W.1, Higgins G.1, Burrell C.3, Li P.1, Qiao M.1 1Institute of Medical and Veterinary Science, Infectious Diseases Laboratories, Adelaide, Australia, 2Royal Adelaide Hosptital, Infectious Diseases Unit, Adelaide, Australia, 3University of Adelaide, School of Molecular and Biomedical Sciences, Adelaide, Australia
TUPEB049 Abstract	An 11-year study of transmitted drug resistance in Victorian patients shows a recent decline in the incidence of TDR and phylogenetic evidence for a common source of infection for multiple patients Presented by Jessica Morris, Australia (TBC) Morris J.1, Chibo D.1, Kaye M.1, Gooey M.1, Carolan L.1, Papadakis A.1, Nicholls J.1, Birch C.1 1Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
TUPEC013 Abstract	An evaluation of medical practitioner’s diagnosis, treatment and care of STI/HIV patients: analyses using simulated patients approach in highly HIV/AIDS prevalence states of India Presented by Pradeep Kumar Bhargava, India (TBC) Bhargava P.K.1, Rajaretnam T.1, Satihal D.1 1Population Research Centre, JSS Institute of Economic Research, Dharwad, India
TUPEB139 Abstract	Antibody response to measles, mumps, rubella re-vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy Presented by Linda Aurpibul, Thailand (TBC) Aurpibul L.1, Puthanakit T.1, Sirisanthana T.1, Sirisanthana V.2 1Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand, 2Faculty of Medicine, Chiang Mai University, Department of Pediatrics, Chiang Mai, Thailand
TUPEA064 Abstract	Apoptosis resistance in HIV-1-persistently infected cells as a model of HIV survival in reservoir cells Presented by Pablo Nicolas Fernandez Larrosa, Argentina (TBC) Fernandez Larrosa P.N.1, Riva D.2, Croci Russo D.3, Bibini M.1, Luzzi R.1, Saracco M.1, Rabinovich G.3, Mersich S.2, Martinez Peralta L.1 1National Reference Center for AIDS, Microbiology Department, School of Medicine, Buenos Aires University, Buenos Aires, Argentina, 2Biologic Chemistry Department, School of Natural Science, Buenos Aires University, Buenos Aires, Argentina, 3Division of Immunogenetics, Hospital de Clinicas 'Jose de San Martin', University of Buenos Aires, Buenos Aires, Argentina
TUPEB020 Abstract	ARCHITECT® HIV Ag/Ab combination assay: correlation of HIV-1 p24 antigen sensitivity and RNA viral load Presented by John Hackett Jr, United States (TBC) Hackett Jr J.1, Swanson P.1, West D.1, Vickstrom R.1, Devare S.G.1, Schochetman G.1, Brennan C.1 1Abbott Laboratories, AIDS Research and Retrovirus Discovery, Abbott Park, United States
TUPEB100 Abstract	Are there gender differences in ART seeking and receipt? Evidence from a population cohort in Rakai, Uganda Presented by Jackson Musuuza, Uganda (TBC) Musuuza J.1, Kigozi G.2, Galiwango R.1, Reynolds S.3, Ndyanabo A.4, Serwadda D.5, Nalugoda F.2, Gray R.6, Wawer M.6, Kiwanuka N.7 1Rakai Health Sciences Program, Anti Retroviral Therapy Department, Kampala, Uganda, 2Rakai Health Sciences Program, Management, Kampala, Uganda, 3NIAID, NIH Baltimore, Management, Baltimore, United States, 4Rakai Health Sciences Program, Kampala, Uganda, 5Makerere University Institute of Public Health, Management, Kampala, Uganda, 6Johns Hopkins School of Medicine, Medicine, Baltimore, United States, 7Case Western University, Cleveland, OH, USA, Management, Kampala, Uganda
TUPEC019 Abstract	Asymptomatic Chalamydia trachomatis and Neisseria gonorrhoea urethritis among HIV-infected patients in Hong Kong detected by urine nucleic acid amplication Test Presented by C.T. Tse, China (TBC) Tse C.T.1, Wong K.H.1, Fong O.W.1, Yeung W.Y.1, Chan W.K.1, Yam W.C.2 1SPP, DH, Hong Kong, China, 2HKU, Hong Kong, China
TUPEC039 Abstract	Barriers to male participation in the prevention of mother-to-child transmission of HIV programme in Mbale, Uganda Presented by Robert Byamugisha, Uganda (TBC) Byamugisha R.1, Tumwine J.K.2, Semiyaga N.3, Tylleskär T.4 1Mbale Regional Referral Hospital, Obstetrics/Gynaecology, Mbale, Uganda, 2Makerere University, Department of Paediatrics and Child Health, P O Box , Kampala, Uganda, Uganda, 3Infectious Diseases Institute Ltd, Partners in Prevention, P O Box , Kampala, Uganda, 4University of Bergen, Centre for International Health, Armauer Hansen Building, N- Bergen, Norway, Norway
TUPEB044 Abstract	Baseline antiretroviral resistance profile and correlation with clinical events in the OPTIMA trial Presented by Mark Holodniy, United States (TBC) Holodniy M.1, Singer J.2, Ayers D.2, Harrigan R.2, Brown S.3, Cameron W.4, Kyriakides T.5, Angus B.6, OPTIMA Study Team 1Department of Veterans Affairs, Office of Public Health Surveillance and Research, Palo Alto, United States, 2Canadian HIV Trials Network, Vancouver, Canada, 3Bronx VA Medical Center, New York, United States, 4University of Ottawa Hospital, Ottawa, Canada, 5West Haven VA CSPCC, West Haven, United States, 6UK MRC, London, United Kingdom
TUPEA060 Abstract	Blood cells intracellular Ca2+ and membrane fluidity changes on antiretrovirals naïve and treated HIV-1 infected patients Presented by Nuno Santos, Portugal (TBC) Santos N.1, Martins-Silva J.1, Doroana M.2, Duarte N.2, Tavares L.2, Antunes F.2, Saldanha C.1 1Faculdade Medicina Universidade Lisboa, Instituto Medicina Molecular, Lisboa, Portugal, 2Hospital Santa Maria, Serviço Infecciologia, Lisboa, Portugal
TUPEA030 Abstract	CD4 composition in GALT is similar in HIV patients treated with HAART compared to those treated with HAART+IL2 Presented by Irini Sereti, United States (TBC) Read S.1, Ciccone E.2, Chairez C.2, Mannon P.2, Davey R.2, Lane H.C.2, Kovacs J.3, Sereti I.2 1National Institutes of Health, Division of AIDS, Bethesda, United States, 2National Institutes of Health, NIAID, Bethesda, United States, 3National Institutes of Health, Critical Care Dpt, Bethesda, United States
TUPEB117 Abstract	Challenges in introducing infant diagnosis of HIV using dried blood spots for DNA PCR in primary health care settings Presented by Isabelle Yersin, Mozambique Jani I.1, Langa J.2, Vaz P.3, Bila D.1, Yersin I.2, Oliveira-Tsiouris F.4, da Silva Z.5, Benech I.6 1National Institute of Health, Imunology, Maputo, Mozambique, 2International Center for AIDS Care and Treatment Programs (ICAP), Mailman School of Public Health, Columbia University Maputo, Mozambique, PMTCT, Maputo, Mozambique, 3Central Hospital,Maputo, Pediatry, Maputo, Mozambique, 4International Center for AIDS Care and Treatment Programs (ICAP), Mailman School of Public Health, Columbia University, New York, New York, United States, 5Ministry of Health (MOH), Maputo, Mozambique, Maputo, Mozambique, 6Centers for Disease Control and Prevention (CDC), Maputo, Mozambique, Maputo, Mozambique
TUPEA078 Abstract	Characterization of memory and cellular immunity in macaques immunized with a novel multivalent HIV-1 peptide vaccine Presented by Ali Azizi, Canada (TBC) Azizi A.1, Anderson D.2, Torres J.3, Ogrel A.4, Diaz-Mitoma F.5 1Research Institute Children's Hospital of Eastern Ontario, Vaccine Research Center, Ottawa, Canada, 2Harvard Medical School, Center for Neurologic Diseases, Boston, United States, 3Department of Medical Microbiology and Immunology, University of California, Davis, United States, 4Variation Biotechnologies Inc., Ottawa, Canada, 5University of Ottawa, Microbiology and Immunology, Ottawa, Canada
TUPEB132 Abstract	Children antiretroviral treatment outcomes after 12 or 24 months of HAART in the HIV care program of North-Western Uganda Presented by Suna Balkan, France (TBC) Ahoua L.1, Guenther G.2, Pinoges L.2, Anguzu P.3, Balkan S.4, Rouzioux C.5, Chaix M.-L.5, Taburet A.M.6, Olson D.7, Olaro C.8, Pujades M.2 1Epicentre, HIV Department, Kampala, Uganda, 2Epicentre, HIV Department, Paris, France, 3Médecins Sans Frontières, Arua Mission, Arua, Uganda, 4Médecins Sans Frontières, Medical Department, Paris, France, 5Necker Hospital, Virology Unit, Paris, France, 6Bicêtre Hospital, Pharmacology Unit, Paris, France, 7Médecins Sans Frontières, Medical Department, New York, United States, 8Arua Regional Refferral Hospital, Arua, Uganda
TUPEA084 Abstract	Chimeric LAMP-1/p55Gag DNA vaccination in neonatal period induces anti-HIV cellular and humoral immune response in mice Presented by PAULA ORDONHEZ RIGATO, Brazil (TBC) Rigato P.O.1, Maciel M.2, Goldoni A.L.1, Fusaro A.E.1, Brito C.A.1, Marques E.T.A.2, August T.2, Duarte A.J.S.1, Sato M.N.1 1Laboratory of Medical Investigation in Dermatology and Immunodeficiencies – 56, School of Medicine, University of São Paulo, São Paulo, Brazil, 2Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, United States
TUPEB101 Abstract	Clinical features of primary HIV-1 infection in women Presented by Amie Meditz, United States (TBC) Meditz A.1, MaWhinney S.1, Feser W.1, Markowitz M.2, Little S.3, Hecht R.4, Daar E.5, Collier C.6, Margolick J.7, Kilby M.8, Routy J.9, Conway B.10, Kaldor J.11, Levy J.4, Schooley R.3, Cooper D.11, Walker B.12, Richman D.3, Connick E.1 1University of Colorado Health Science Center, Denver, United States, 2Aaron Diamond AIDS Research Center, Rockefeller University, New York, United States, 3University of California, San Diego, United States, 4University of California, San Francisco, United States, 5University of California, Los Angeles, United States, 6University of Washington, Seattle, United States, 7Johns Hopkins University, Baltimore, United States, 8University of Alabama, Birmingham, United States, 9McGill Universiy Health Center, Montreal, Canada, 10University of British Columbia, Vancouver, Canada, 11National Centre for HIV Epidemiology and Clinical Research, Sydney, Australia, 12Partners AIDS Research Center, Boston, United States
TUPEA077 Abstract	Clinical trial of recombinant gag-env HIV1 protein based vaccine VICHREPOL in healthy adults Presented by Igor Sidorovich, Russian Federation Korobova S.1, Nikolaeva I.1, Chevalier A.1, Gornostaeva Y.1, Trubcheniniva L.1, Gorbunova Z.1, Gudima G.1, Pinegin B.1, Chernousov A.1, Petrova T.2, Trofimov D.2, Sidorovich I.1 1Institute of Immunology, Moscow, Russian Federation, 2DNA Tecnology Ltd, Moscow, Russian Federation
TUPEB085 Abstract	Comparison of interruption and re-treatment with recombinant human growth hormone (r-hGH) with an induction-maintenance-re-induction regimen in patients (pts) with HIV-associated adipose redistribution syndrome (HARS): effects on trunk fat (TF) at 48 weeks (wks) Presented by Stephen Brown, United States (TBC) Brown S.1, Moe A.2, Freedland E.S.3 1AIDS Research Alliance, Los Angeles, United States, 2UCLA, Los Angeles, United States, 3EMD Serono Inc., Rockland, United States
TUPEB093 Abstract	Continuing improvements in survival in the era of HAART Presented by Kholoud Porter, United Kingdom (TBC) Porter K.1, Bhaskaran K.1, CASCADE Collaboration 1MRC Clinical Trials Unit, London, United Kingdom
TUPEC045 Abstract	Contraception – an effective and underutilized approach to preventing HIV sequelae Presented by Willard Cates Jr, United States Cates, Jr. W.1, Reynolds H.1, Wilcher R.1 1Family Health International, Durham, NC, United States
TUPEB065 Abstract	Coronary artery disease in HIV-infected patients Presented by Robert Micheletti, United States (TBC) Micheletti R.1, Fishbein G.1, Currier J.1, Singer E.1, Fishbein M.1 1University of California at Los Angeles, Los Angeles, CA, United States
TUPEB027 Abstract	Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use Presented by Veronica Briz, Spain (TBC) Briz V.1, Poveda E.1, Roulet V.2, González M.d.M.1, Faudon J.-L.3, Scrabal K.2, Soriano V.1 1Hospital Carlos III, Infectious Disease Department, Madrid, Spain, 2Eurofins Viralliance, Michigan, United States, 3Bioalliance Pharma, Paris, France
TUPEB111 Abstract	Counseling and testing of Ethiopian women with unknown HIV status at delivery: a window of opportunity Presented by Zenebe Melaku, Ethiopia (TBC) Melaku Z.1, Melkamu A.2, Tizazu G.1, Alemu A.1, Gashu N.1, Rabkin M.3 1Columbia University, ICAP Ethiopia, Addis Ababa, Ethiopia, 2Dil-Chora Hospital, Dire Dawa, Ethiopia, 3Columbia University, ICAP-NY, New York, United States
TUPEC001 Abstract	Creating awareness about microbicides to low literate audience in rural settings Presented by Abdullrahman Orosanya, Nigeria (TBC) Afolabi R.1, Orosanya A.2 1Potters Care Organization, Suppport Group Cordinator, Lagos, Nigeria, 2Concern Conscience International, Research and Resource, Lagos, Nigeria
TUPEA052 Abstract	DC-SIGNR polymorphisms and the association with HIV-1 infection within the Chinese population Presented by Hui Wang, China (TBC) Wang H.1, Wang C.2, Xiao X.3, Feng T.4, Zhou H.5, Liu F.6, Zhu T.7, Zhou B.1 1Shenzhen Municipal Hospital of Infectious Dieases, Department of AIDS Clinical Research, Shenzhen, China, 2University of Washington School of Medicine, Departmemt of Laboratory Medicine, Seattle, United States, 3Jinan University, Center for HIV Genomics and Vaccines, Guangzhou, China, 4Shenzhen Municipal Center for Disease Control and Prevention, Shenzhen, China, 5Shenzhen STD Control Center, Shenzhen, China, 6Dongguan Blood center, Dongguan, China, 7University of Washington School of Medicine, Seattle, United States
TUPEB094 Abstract	Declining mortality in people with HIV in Hubei province, China, 2002 - 2006: results of an international partnership to train and mentor county, village, and township health care workers Presented by Renslow Sherer, United States (TBC) Sherer R.1, Zhan F.2, Teter C.3, Yang F.2, Gui X.4, Liu Ping D.5, Liang K.5, Qian H.6 1Project HOPE, University of Chicago, Evanston, IL, United States, 2Hubei Province Centers for Disease Control, Wuhan, China, 3Project HOPE, Millwood, United States, 4Wuhan University, Wuhan, China, 5Project HOPE Wuhan, Wuhan, China, 6Project HOPE Wuhan, Millwood, China
TUPEA026 Abstract	Defining CD4 specific immune response in seroconverters enrolled in an RCT of primary HIV infection Presented by Rodney Phillips, United Kingdom (TBC) Phillips R.1, Lee K.2, Robinson N.1, Brown H.1, Ohm Laursen L.1, Fidler S.3, Scriba T.1, Oxenius A.1, Porter K.2, Weber J.3, SPARTAC Trial Investigators 1University of Oxford, The Peter Medawar Building for Pathogen Research, Oxford, United Kingdom, 2MRC Clinical Trials Unit, London, United Kingdom, 3Imperial College, London, United Kingdom
TUPEA075 Abstract	Design, development and preclinical testing of HIV-1 Indian subtype C tat DNA/MVA vaccine Presented by Huma Qureshi, India (TBC) Qureshi H.1, Prasad V.1, Das B.1, Seth P.1 1A.I.I.M.S, Microbiology, New Delhi, India
TUPEB021 Abstract	Detection of p24 erythrocyte associated antigen in HIV positive patients with previous undetectable plasma viral load Presented by María Sol dos Ramos Farías, Argentina (TBC) dos Ramos Farías M.S.1, Garcia M.N.1, Schvachsa N.1, Rabinovich R.D.1, Ávila M.M.1 1National Reference Center for AIDS, Department of Microbiology, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina
TUPEB035 Abstract	Detection of the onset of drug resistant mutations in pregnant women receiving single dose nevirapine in Namakkal, Tamilnadu, using oligonucleotide ligation assay Presented by Saramma Mini Jacob, India (TBC) Jacob S.M.1, Durairaj A.1, Vijayakumari J.J.1, Srijayanth P.1, Melvin A.J.2, Frenkel L.M.3, Samuel N.M.1 1Tamilnadu Dr MGR Medical University, Department of Experimental Medicine, Chennai, India, 2Children's Hospital and Regional Medical Center, Division of Infectious Diseases, Seattle, United States, 3University of Washington and Children's Hospital, Pediatrics and Laboratory Medicine, Seattle, United States
TUPEB090 Abstract	Determinants associated with asymptomatic HIV disease in the Australian long-term non-progressor cohort Presented by Linda Gelgor, Australia (TBC) Gelgor L.1, Anderson B.2, Baker D.3, Finlayson R.4, Genn W.3, McFarlane R.3, McMurchie M.3, Kelleher A.1, Kaldor J.1, Long Term Non-Progressor Study Group 1University of New South Wales, National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia, 2St Leonards Medical Centre, Sydney, Australia, 3407 Doctors, Sydney, Australia, 4Taylor Square Private Clinic, Sydney, Australia
TUPEB080 Abstract	Determination of body composition changes by total body DEXA after 48 weeks of treatment with once-daily fosamprenavir (FPV) boosted with two different doses of ritonavir(r) plus abacavir (ABC)/lamivudine(3TC): COL100758 Presented by Charles Hicks, United States Wohl D.1, Lancaster T.2, DeJesus E.3, Sloan L.4, Sension M.5, Liao Q.2, Hicks C.6 1University of North Carolina at Chapel Hill, Chapel Hill, United States, 2GlaxoSmithKline, Research Triangle Park, United States, 3Orlando Immunology Ctr, Orlando, United States, 4North Texas Infectious Disease Consultants, Dallas, United States, 5Comprehensive Care Center, Ft. Lauderdale, United States, 6Duke University, Infectious Diseases, Durham, United States
TUPEC025 Abstract	Determining optimal breastfeeding in HIV affected resource-limited settings Presented by Danstan Bagenda, Uganda (TBC) Bagenda D.1 1Makerere University- Johns Hopkins University Research Collaboration (Kampala)/Johns Hopkins Fogarty (Baltimore), Kampala, Uganda
TUPEB028 Abstract	Development of a genotype resistance test of GP41 region for patients receiving fusion inhibitors Presented by Lisa Morris, Australia (TBC) Morris L.1, Greengrass V.1, Plate M.1, Crowe S.1 1Burnet Institute, Clinical Research Facility, Melbourne, Australia
TUPEA048 Abstract	Development of macrophage targeted therapy for treatment of HIV associated neurological disease: results of two SIV associated encephalitis clinical studies with PA001 Presented by Michael S. McGrath, United States (TBC) McGrath M.S.1, Hadlock K.G.2, Kim W.K.3, Williams K.C.3 1University of California, San Francisco, San Francisco, CA, United States, 2Pathologica, Burlingame, CA, United States, 3Harvard University/Beth Israel Deaconess Medical Center, Boston, MA, United States
TUPEB108 Abstract	Development of phenotypic HIV-1 drug resistance following exposure to single dose nevirapine Presented by Adriaan Basson, South Africa (TBC) Basson A.1, Ntsala M.1, Tlale E.1, Corrigan G.2, Shao X.2, Martinson N.3, Martinson N.4, Gray G.3, McIntyre J.3, Puren A.1, Morris L.1 1National Institute for Communicable Diseases (NICD), AIDS Research Unit, Johannesburg, South Africa, 2Cavidi Tech., Uppsala, Sweden, 3Perinatal HIV Research Unit, Johannesburg, South Africa, 4John Hopkins University, School of Medicine, Baltimore, United States
TUPEB066 Abstract	Differences in cardiac output and total peripheral resistance in patients HIV-patients with and without lipodystrophy Presented by Georg Behrens, Germany (TBC) Kaspari M.1, Wiese M.1, Moebius U.1, Schmidt R.E.1, Behrens G.1 1Hannover Medical School, Clinical Immunology, Hannover, Germany
TUPEB046 Abstract	Differences in frequencies of PI-resistance mutations of HIV-1 from different subtypes (B, C and F) in a cohort of patients failing ARV therapy in Brazil Presented by Mônica Arruda, Brazil (TBC) Arruda M.1, Pires A.F.1, Silva R.M.2, Nobre F.2, Tanuri A.3, Brindeiro R.3, and the Brazilian RENAGENO Network 1Federal University of Rio de Janeiro, Department of Biochemistry, Rio de Janeiro, Brazil, 2COPPE-Federal University of Rio de Janeiro, Program of Biomedical Engineering, Rio de Janeiro, Brazil, 3Federal University of Rio de Janeiro, Department of Genetics, Rio de Janeiro, Brazil
TUPEA051 Abstract	Differential Kynurenine Pathway (KP) induction by HIV strains Presented by Apsara Kandanearatchi, Australia (TBC) Kandanearatchi A.1, Pemberton L.1, Wilkinson J.2, Maddocks S.3, Cunningham A.3, Brew B.4 1Centre for Immunology, St Vincent's Hospital/ UNSW, Sydney, Australia, 2Centre for Immunology, Biotron, Sydney, Australia, 3Millennium Building, University of Sydney, Westmead, Australia, 4St Vincent's Hospital/ UNSW, Neurology, Sydney, Australia
TUPEB060 Abstract	Discordances in HIV-1 viral load quantification between Roche Cobas® Amplicor® HIV-1 Monitor v 1.5 and Roche Cobas® Ampliprep/Cobas® Taqman® HIV-1 assays Presented by Diane Descamps, France (TBC) Damond F.1, Roquebert B.1, Bénard A.2, Collin G.1, Miceli M.1, Yéni P.3, Brun-Vézinet F.1, Descamps D.1 1Hopital Bichat-Claude Bernard, Laboratoire de Virologie, Paris, France, 2INSERM U593, Bordeaux, France, 3Hopital Bichat-Claude Bernard, SMIT, Paris, France
TUPEA056 Abstract	Distribution of CCR-5 genotypes and HLA class I B alleles in HIV-1 infected and uninfected injecting drug users from Rio de Janeiro, Brazil Presented by Sylvia Lopes Maia Teixeira, Brazil (TBC) Teixeira S.L.M.1, Bastos F.I.2, Hacker M.A.2, Morgado M.G.1 1Laboratory of AIDS and Molecular Immunology, Department of Immunology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, FIOCRUZ, Rio de Janeiro, Brazil, 2Center for Information on Science and Technology, Department of Health Information, Oswaldo Cruz Foundation, FIOCRUZ, Rio de Janeiro, Brazil
TUPEB088 Abstract	Does antiretroviral therapy cause osteopaenia and osteoporosis? Presented by Shashikant Nawale, India (TBC) Nawale S.1, Chandanwale A.1, Giripunje N.1, Jadhav S.1 1Sir J. J. Hospital, Orthopaedics, Mumbai, India
TUPEB134 Abstract	Does autoimmunity contribute to thyroid dysfunction in children with perinatal HIV infection in the highly active antiretroviral therapy (HAART) era? Presented by Ninad Desai, United States (TBC) Desai N.1, Bailey S.A.1, Quintos J.1 1Kings County Hospital Center & SUNY Downstate, Pediatrics, Brooklyn, United States
TUPEC036 Abstract	Domestic violence and prevention of mother–to–child transmission of HIV–1 Presented by Namukwaya Janat, Uganda (TBC) Janat N.1 1Makerere University, Department Of Medicine, Kampala, Uganda
TUPEB125 Abstract	Dose selection of darunavir co-administered with low-dose ritonavir (DRV/r) in treatment-experienced HIV-1-infected children and adolescents Presented by Sabrina Spinosa-Guzman, Belgium (TBC) Spinosa-Guzman S.1, Sekar V.J.2, Van Baelen B.1, De Greef R.1, Hoetelmans R.M.1, Vangeneugden T.1, De Pauw M.1, Lefebvre E.1 1Tibotec BVBA, Mechelen, Belgium, 2Tibotec Inc., Yardley, United States
TUPEB045 Abstract	Drug resistance associated mutations in HIV-1 infected patients failing antiretroviral therapy in Southern India Presented by MADHAVAN VIDYA, India (TBC) Vidya M.1, Balakrishnan P.1, Kumarasamy N.1, Solomon S.1, Saravanan S.1, Anitha J.C.1, Murugavel K.G.1, Sunil S.S.1, Bharat R.2, Thyagarajan S.1, David K.3, Kenneth H.M.2, Rami K.2 1YRGCARE, Centre For AIDS Research & Education, Chennai, India, 2Division of Infectious Diseases, Department of Medicine, Brown University Medical School, Providence, United States, 3Division of Infectious Diseases, Stanford University, Stanford, United States
TUPEB048 Abstract	Drug resistance profile among HAART-naïve and -exposed patients failing therapy in Burkina Faso Presented by Denis Tebit, United States (TBC) Tebit D.1, Sangare L.2, Yameogo S.2, Makamste A.2, Somlare H.2, Bado G.2, Kouldiaty B.2, Sathiandee K.3, Tiba F.3, Diallo I.4, Zoungrana L.4, Drabo J.4, Kraeusslich H.-G.3 1Case Western Reserve University, Infectious Diseases, Cleveland, United States, 2Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso, Service de Bacteriologie-Virologie, Ouagadougou, Burkina Faso, 3Universitaetsklinikum Heidelberg, Abteilung Virologie, Heidelberg, Germany, 4Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso, Service de Medicine Interne, Ouagadougou, Burkina Faso
TUPEA079 Abstract	Dual serotype adenoviral-based vaccination during antiretroviral treated chronic SIV infection elicits robust cellular immunity and limited virologic containment at treatment cessation Presented by Adam C. Soloff, United States (TBC) Soloff A.C.1, Liu X.D.1, Gao W.2, Gambotto A.2, Barratt-Boyes S.M.1 1University of Pittsburgh, Center for Vaccine Research, Pittsburgh, United States, 2University of Pittsburgh, Surgery, Pittsburgh, United States
TUPEB061 Abstract	Duration of infection and low CD4:CD8 ratio correlate with CXCR4 utilization among HIV-1 subtype CRF01_AE Presented by Utaiwan Utaipat, Thailand (TBC) Utaipat U.1, Keitkarn J.1, Sakkhachornphop S.1, Tovanabutra S.2, Beyrer C.3, Khamboonrueng C.1, Sirisanthana T.1, Duerr A.4, Suriyanon V.1, Nelson K.E.3 1Research Institutes for Health Sciences, Chiang Mai University, Chiang Mai, Thailand, 2U.S. Military HIV Research Program (USMHRP), Henry M. Jackson Foundation, Rockville, MD, United States, 3Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States, 4Centers for Disease Control and Prevention, Atlanta, GA, United States
TUPEA006 Abstract	Dynamic force spectroscopy reveals a complex interaction between 2F5 monoclonal antibody and its epitope Presented by Rajiv Tawar, United Kingdom (TBC) Tawar R.1, Allen S.2, Williams P.2, Ball J.1 1Institute of Infection Immunity and Inflammation, School of Molecular Medical Sciences, Nottingham, United Kingdom, 2Laboratory of Biophysics and Surface Analysis, School of Pharmacy, Nottingham, United Kingdom
TUPEB038 Abstract	Dynamics of mutations during treatment interruption after successfully HAART-regimens Presented by Francesca Prati, Italy (TBC) Prati F.1, Ceccherini-Silberstein F.2, Nasi M.3, Sabbatini F.1, Gori C.4, Borghi V.1, Esposito R.1, Cossarizza A.3, Mussini C.1, Perno C.F.2 1Clinical of Infectious Disease, Department of Medicine and Medical specialities, Modena, Italy, 2Tor Vergata University, Department of Experimental Medicine, Rome, Italy, 3University of Modena, Department of Biomedical Sciences, Modena, Italy, 4National Institute for Infectious Diseases L. Spallanzani, Rome, Italy
TUPEB091 Abstract	Early CD4 and virological markers progression in long term non progressors followed since HIV-diagnosis in the ANRS SEROCO cohort Presented by Yoann Madec, France (TBC) Madec Y.1, Boufassa F.2, Veronique A.-F.3, Hendou S.2, Boucherit S.2, Surzyn J.2, Rouzioux C.3, Meyer L.2, SEROCO study group 1Institut Pasteur, Unité d'Epidemiologie des Maladies Emergentes, Paris, France, 2INSERM U822, Le Kremlin-Bicetre, France, 3Hopital Necker, Laboratoire de Bactériologie - Virologie, Paris, France
TUPEB037 Abstract	Effect of tenofovir-selected RT K65R on response to subsequent regimens Presented by Wesley Shealey, United States (TBC) Shealey W.1, Shepherd B.1, Bress J.1, Kheshti A.2, Blackwell B.2, Barkanic G.2, Sterling T.1, D'Aquila R.1 1Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States, 2Comprehensive Care Center, Nashville, TN, United States
TUPEA016 Abstract	Effective CD8(+) cell responses against SIV superchallenge in SHIV-controllers Presented by Tetsuo Tsukamoto, Japan (TBC) Tsukamoto T.1, Yuasa M.1, Kawada M.1, Takeda A.1, Matano T.1 1International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
TUPEA072 Abstract	Effective immune control of simian/human immunodeficiency virus in pigtail macques by combined T cell and neutralizing antibody responses Presented by Jeanette Caroline Reece, Australia (TBC) Reece J.C.1, Stratov I.1, Batten C.J.1, Chea S.1, Montefiori D.C.2, De Rose R.1, Kent S.J.1 1University of Melbourne, Department of Microbiology and Immunology, Parkville, Australia, 2Duke University Medical Center, Department of Surgery, Durham, United States
TUPEB072 Abstract	Effects of tipranavir/r (500/200 or 500/100 mg BID) in comparison with lopinavir/r (400/100 mg BID) on changes in body composition and metabolic parameters in ARV-naïve patients over 48 weeks Presented by Andrew Carr, Australia (TBC) Carr A.1, Zajdenverg R.2, Workman C.3, Gatell J.4, Cahn P.5, Ritzhaupt A.6, Zhang W.7, Chaves R.6 1St Vincent's Hospital, Sydney, Sydney, Australia, 2Projeto Praça Onze – UFRJ Hospital Escola São Francisco de Assis, Rio de Janeiro, Brazil, 3AIDS Research Initiative, Sydney, Australia, 4Hospital Clinic de Barcelona, Barcelona, Spain, 5Fundacion Huesped, Buenos Aires, Argentina, 6Boehringer Ingelheim GmbH, Biberach an der Riss, Germany, 7Boehringer Pharmaceuticals Inc, Ridgefield, United States
TUPEB128 Abstract	Efficacy and safety of non nucleoside reverse transcriptase inhibitor (NNRTI) based highly active antiretroviral therapy (HAART) in Thai children with HIV Presented by Torsak Bunupuradah, Thailand (TBC) Bunupuradah T.1, Puthanakit T.1, Boonrak P.1, Butterworth O.1, Mengthaisong T.1, Intasan J.1, Ubolyam S.1, Kosalaraksa P.2, Engchanil C.2, Pancharoen C.3, Lumbiganond P.2, Phanuphak P.1, Ananworanich J.4, HIV-NAT Pediatric Study Team 1The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand, 2Khon Kaen University, Khon Kaen, Thailand, 3Chulalongkorn University, Bangkok, Thailand, 4HIV-NAT and South East Asia Research Collaboration with Hawaii (SEARCH), Bangkok, Thailand
TUPEA005 Abstract	Enhancement of HIV replication in immature dendritic cells in the presence of CD4+ T lymphocytes: inhibition of HIV transfer by monoclonal neutralizing antibodies Presented by Vincent Holl, France (TBC) Xu K.1, Holl V.1, Peressin M.1, Decoville T.1, Schmidt S.1, Aubertin A.-M.1, Moog C.1 1UMR INSERM/ULP, Institute of Virology, Strasbourg, France
TUPEB056 Abstract	Epidemiology of non-B clade forms of HIV-1 in MSM in the UK Presented by Julie Fox, United Kingdom (TBC) Fox J.1, Duda A.2, Kaye S.1, Green H.3, Dunn D.3, McClure M.1, Fidler S.1, UK Collaborative Group on HIV Drug Resistance and UK CHIC Study 1Imperial College, Infectious Diseases, London, United Kingdom, 2University of Oxford, Immunology, Oxford, United Kingdom, 3MRC, London, United Kingdom
TUPEB103 Abstract	Evaluation of cervical intraepithelial neoplasia (CIN) in postmenopausal HIV positive women Presented by Claudia Ferreira, France (TBC) Ferreira C.1, Crenn-Hebert C.1, Alavi-Moghaddam M.2, Gavard L.3, Mandelbrot L.3 1Assistance Publique-Hopitaux de Paris, Louis Mourier Hospital, Colombes, France, 2Department of Clinical Immunology APHP Henri Mondor, Créteil, France, 3Assistance Publique-Hopitaux de Paris, Louis Mourier Hospital, Colombes; Paris 7 University, Paris, France
TUPEB123 Abstract	Evaluation of Efficacy of WHO case definition criteria for diagnosis of AIDS in children Presented by Rasika Gadkari, India (TBC) Gadkari R.1, Dhande L.1, Chande C.1, Ughade S.1, Warhadpande U.1 1Govt. Medical College, Pathology, Nagpur, India
TUPEB015 Abstract	Evaluation of the blood stabilizer and Cyto-Chex® BCT (blood collection tube) for use in conjunction with a low cost HIV-RT test used to measure viral load in HIV patients Presented by Megan Plate, Australia (TBC) Plate M.1, Rooijen L.2, Greengrass V.1, Steele P.1, Morris L.1, Crowe S.3 1Burnet Institute, Clinical Research Laboratory, Melbourne, Australia, 2Free University, Amsterdam, Amsterdam, Netherlands, 3Burnet Institute, AIDS Pathogenesis Unit, Melbourne, Australia
TUPEB019 Abstract	Evaluation of the Cavidi ExaVir™ Load quantitative HIV RT load kit as an alternative HIV viral load monitoring test for use in Melbourne Presented by Vicki Greengrass, Australia (TBC) Greengrass V.1, Plate M.1, Steele P.1, van Rooijen L.2, Morris L.1, Crowe S.1 1Macfarlane Burnet Institute for Medical Research and Public Health, Clinical Research Laboratory, Melbourne, Australia, 2Free University, Amsterdam, Netherlands
TUPEB069 Abstract	Evaluation of the impact of highly active antiretroviral therapy (HAART) on lipid profiles – data from the 24-week interim analysis of the Gemini Study: saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD in ARV-naïve HIV-1-infected patients Presented by Sharon Walmsley, Canada Walmsley S.1, Bredeek U.2, Avihingsanon A.3, Slim J.4, Guittari C.5 1University of Toronto, Medicine, Toronto, Canada, 2El Rio, Special Immunology Associates, Tucson, United States, 3HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, 4St Michael's Medical Center, Newark, United States, 5Roche, Nutley, United States
TUPEB014 Abstract	Evaluation of the use of dried blood spots or dried plasma spots in combination with the Cavidi Exavir® Load RT Assay Presented by Lisette Babette van Rooijen, Australia (TBC) van Rooijen L.B.1, Morris L.1, Steele P.1, Greengrass V.1, Plate M.1, Crowe S.1 1Burnet Institute for Medical Research and Public Health, Clinical Research Laboratory, Melbourne, Australia
TUPEB122 Abstract	Evaluation of the WHO clinical case definition of AIDS for pediatric AIDS in the Indian context Presented by Tripti Pensi, India Banerjee T.1, Grover G.1, Pensi T.2, Gadpayle A.K.3 1University of Delhi, Statistics, Delhi, India, 2Dr.Ram Manohar Lohia Hospital, Pediatrics, Delhi, India, 3Dr.Ram Manohar Lohia Hospital, Medicine, Delhi, India
TUPEB047 Abstract	Evolution of antiretroviral resistance in Ugandan patients on first-line HAART with persistent virologic failure Presented by Steven Reynolds, United States (TBC) Reynolds S.1, Dybul M.2, Daucher M.3, Kabuye G.4, Harvey R.3, Kityo C.4, Dewar R.3, Quinn T.3, Mugyenyi P.4 1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Washington, United States, 2US Department of State, Office of The Global AIDS Coordinator, Washington, United States, 3National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States, 4Joint Clinical Research Center, Kampala, Uganda
TUPEB042 Abstract	Evolution of drug resistance among patients failing highly active antiretroviral therapy in a supervised treatment setting Presented by Delivette Castor, United States (TBC) Castor D.1, Hammer S.2, Hoover D.3, Vlahov D.4 1Rockefeller University, Aaron Diamond AIDS Research Center, NY, United States, 2Columbia University, College of Physicians and Surgeons, NY, United States, 3Rutgers, The State University of New Jersey, Statistics, Piscataway, United States, 4New York Academy of Medicine, Center for Urban Epidemiologic Studies, NY, United States
TUPEC006 Abstract	Existing gaps in microbicide research and development process: perspectives from trial participants Presented by Morenike Ukpong, Nigeria (TBC) Ukpong M.1, Oladapo O.1 1Nigeria HIV Vaccine and Microbicide Advocacy Group, Lagos, Nigeria
TUPEB105 Abstract	Expanded access to PMTCT: intrapartum HIV counseling and testing in a hospital setting, Kampala Uganda Presented by Sam Ononge, Uganda (TBC) Ononge S.1, Mirembe F.1, Clemensia N.1, Fowler M.G.1, Mmiiro F.1, Antelman G.1 1MUJHU Research Collaboration, Obstetrics and Gynaecology, Kampala, Uganda
TUPEA033 Abstract	Extracellular high mobility group box protein 1 inhibits R5 and X4 HIV replication in monocytic cells Presented by Guido Poli, Italy (TBC) Alfano M.1, Cassetta L.1, Fortunato O.1, Bianchi M.1, Poli G.1 1San Raffaele Scientific Institute, Immunology and Infectious Diseases, Milano, Italy
TUPEB076 Abstract	Ezetimibe combined with low dose statin effectively lowers LDL in protease inhibitor treated patients Presented by Olga M. Klibanov, United States (TBC) Klibanov O.M.1, Gaughan J.P.1, Tedaldi E.M.1, Lattanzi K.M.1, Parekh A.N.1, Gallagher K.A.2, Rivero R.O.2, van den Berg-Wolf M.1 1Temple University, Philadelphia, United States, 2Abbott Labs, Abbott Park, United States
TUPEB075 Abstract	Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV Presented by Matthew Bennett, Canada (TBC) Bennett M.1, Johns K.1, Bondy G.2 1University of British Columbia, Medicine, Vancouver, Canada, 2Immunodeficiency Clinic-HIV Metabolic Clinic, St. Paul’s Hospital, University of British Columbia, Medicine, Vancouver, Canada
TUPEC026 Abstract	Factors affecting selection and adherence to infant feeding choice made by HIV-positive mothers - participating in the Kesho Bora WHO project, Bobo Dioulasso, Burkina Faso Presented by Kossiwavi Amewono AYASSOU, Burkina Faso (TBC) Ayassou K.A.1, Saher A.1, Cames C.1, Ky-Zerbo O.1, Bonkoungou J.1, Kone H.1, Ouedraogo S.1, Devincenzi I.1, Meda N.1, Simondon K.1, For the Kesho Bora WHO Project 1IRD/Centre Muraz, UR 024, Bobo-Dioulasso, Burkina Faso
TUPEB006 Abstract	Factors associated with voluntary counseling and testing (VCT) utilization among young adults in rural Rakai, Uganda Presented by Betty Nantume, Uganda (TBC) Nantume B.1, Makumbi F.1, Nalugoda F.1, Kigozi G.1, Kagaayi J.1 1Rakai Health Sciences Program, Kalisizo, Uganda
TUPEA059 Abstract	Fc receptor γ-chain expression in peripheral blood mononuclear cell populations of HIV-1-infected individuals Presented by Edwin Leeansyah, Australia (TBC) Leeansyah E.1, Paukovics G.1, Crowe S.M.1, Jaworowski A.1 1Burnet Institute, AIDS Pathogenesis and Clinical Research Program, Melbourne, Australia
TUPEB010 Abstract	Field evaluation of an HIV rapid test algorithm for the rapid diagnosis of HIV infection in Brazil Presented by Cristine Ferreira, Brazil da Costa Ferreira Junior O.1, Ferreira C.2, Riedel M.3, Visinoni Widolin M.3, Sasazawa Ito T.3, Westman S.4, Brady W.4 1Federal University of Rio de Janeiro, Institute of Biology, Rio de Janeiro, Brazil, 2Ministry of Health of Brazil, Laboratory Unit, Brasilia, Brazil, 3Municipal Laboratory of Curitiba, Curitiba, Brazil, 4Centers for Disease Control and Prevention, Global Aids Programme, Brasilia, Brazil
TUPEB016 Abstract	Field evaluation of Calypte AWARE HIV-1/2 OMT rapid tests for the detection of antibodies to HIV 1+ 2 in human oral mucosal transudate among ANGAZA VCT clients in Tanzania Presented by Willy Urassa, Tanzania, United Republic of (TBC) Urassa W.1, Ochieng D.2, Kasubi M.3 1Muhimbili University College, Microbiology/Immunology, Dar es Salaam, Tanzania, United Republic of, 2AMREF, Laboratory, Dar es salaam, Tanzania, United Republic of, 3Muhimbili National Hospital, Microbiology, Dar es Salaam, Tanzania, United Republic of
TUPEB018 Abstract	Field evaluation of rapid serologic tests for screening HIV infection using sera from rakai cohort, Southwestern Uganda Presented by Charles kagulire, Uganda (TBC) Kagulire C.1, Rakai Health Sciences Program 1Uganda Virus Research Institute, Rakai Health Sciences Program, Entebbe, Uganda
TUPEB032 Abstract	First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137) Presented by Edwin DeJesus, United States (TBC) DeJesus E.1, Cohen C.2, Elion R.3, Ortiz R.1, Maroldo L.4, Franson S.4, Pesano R.4 1Orlando Immunology Center, Orlando, United States, 2CRI New England, Boston, United States, 3George Washington University, Washington DC, United States, 4Monogram Biosciences, San Francisco, United States
TUPEB030 Abstract	French observatory of HIV-1 infected patients experiencing virological failure while receiving enfuvirtide salvage antiretroviral therapy containing regimen Presented by Diane Descamps, France (TBC) Descamps D.1, Assoumou L.2, Masquelier B.3, Peytavin G.4, Saidi S.2, Tamalet C.5, Marcelin A.-G.6, Cottalorda J.7, Plantier J.-C.8, Montes B.9, Izopet J.10, Yerly S.11, Schneider V.12, Delaugerre C.13, Ferre V.14, Ruffault A.15, Idri N.16, Morand-Joubert L.17, Chaix M.-L.18, Calvez V.6, Françoise B.-V.1, Costagliola D.2, ANRS-AC11 Resistance Study Group 1Hopital Bichat-Claude Bernard, Laboratoire de Virologie, Paris, France, 2Inserm, UMR 720, Paris, France, 3Hopital Pellegrin, Laboratoire de Virologie, Bordeaux, France, 4Hopital Bichat-Claude Bernard, Laboratoire de Toxicologie, Paris, France, 5Hopital de la Timone, laboratoire de Virologie, Marseille, France, 6Hopital Pitié-Salpétrière, Laboratoire de Virologie, Paris, France, 7CHU de Nice, Laboratoire de Virologie, Nice, France, 8CHU de Rouen, Laboratoire de Virologie, Rouen, France, 9CHU Montpellier, Laboratoire de Virologie, Montpellier, France, 10Hopital Purpan, Laboratoire de Virologie, Toulouse, France, 11Hopital de Genève, Laboratoire de Virologie, Genève, Switzerland, 12Hopital Tenon, Laboratoire de Virologie, Paris, France, 13Hopital Ambroise Paré, Laboratoire de Virologie, Boulogne, France, 14CHU de Nantes, Laboratoire de
TUPEB057 Abstract	Frequency distribution of mutations in HIV-1 subtypes B and BF in treatment-experienced patients from Argentina Presented by Carina Cesar, Argentina (TBC) Cesar C.1, Krolewiecki A.1, Zapiola I.2, Bouzas M.B.2, Gun A.1, Patterson P.1, Sued O.1, Abusamra L.1, Cahn P.1 1Fundación Huésped, Investigaciones Clínicas, Buenos Aires, Argentina, 2Fundación Huésped, Virology, Buenos Aires, Argentina
TUPEA002 Abstract	Functional study of peripheral blood dendritic cells isolated from HIV infected patients before and after HAART Presented by Phennapha Klangsinsirikul, Thailand (TBC) Klangsinsirikul P.1, Dettrairat S.1, Leechanachai P.1, Ngo-Giang-Huong N.2 1Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand, 2The Program for HIV Prevention and Treatment, Chiang Mai, Thailand
TUPEA018 Abstract	Gag-specific CD4+IFNγ+IL-2+ T cells facilitate the control of viremia and preservation of central memory CD4+ T cells in SIV-infected macaques Presented by Rosemarie Mason, Australia (TBC) Mason R.1, DeRose R.1, Fernandez C.1, Kent S.1 1University of Melbourne, Microbiology & Immunology, Melbourne, Australia
TUPEB099 Abstract	Gender influence on utilisation and outcomes of HIV/AIDS care and therapy at two national teaching hospitals in Uganda, 2007 Presented by Gideon Amanyire, Uganda (TBC) Amanyire G.1, Mwesigire D.2, Okiror D.3, Mayanja B.4, Muyindike W.5, Ouma J.6, Elyanu P.7, Wanyenze R.8, Kamya M.9, Sewankambo N.S.10 1Makerere University and Mulago Hospital Complex, Administration and Mnagement, Mbarara, Uganda, 2Makerere University and Mulago Hospital Complex, Clinical Services, Kampala, Uganda, 3Makerere University and Mulago Hospital Complex, Clinical Services, Mbarara, Uganda, 4Mbarara University Teaching Hospital, Department of Medicine, Mbarara, Uganda, 5Mbarara University Teaching Hospital, Medical Department, Mbarara, Uganda, 6Makerere University and Mulago Hospital Complex, Statistics, Kampala, Uganda, 7Makerere University and Mulago Hospital Complex, Statistics, Mbarara, Uganda, 8Makerere University and Mulago Hospital Complex, Administration and Management, Kampala, Uganda, 9Mulago - Mbarara Teaching Hospitals Joint AIDS Program (MJAP), Medical Department, Kampala, Uganda, 10Makerere University and Mulago Hospital Complex, Medical Department, Kampala, Uganda
TUPEA022 Abstract	Generation of monoclonal antibodies cross-reactive for the wild type and an escape mutant of an immunodominant CTL epitope Presented by Jun-ichi Nunoya, Japan (TBC) Nunoya J.-I.1, Nakashima T.2, Kawana-Tachikawa A.1, Ito Y.3, Sugimura K.3, Iwamoto A.1 1The institute of medical science, University of Tokyo, Division of Infectious Diseases, Advanced Clinical Research Center, Tokyo, Japan, 2The Chemo-Sero-Therapeutic Research Institute, Division 2, First Research Department, Kikuchi Research Center, Kumamoto, Japan, 3Kagoshima University, Department of Bioengineering, Faculty of Engineering, Kagoshima, Japan
TUPEC017 Abstract	Genital tract HIV-1 RNA shedding and asymptomatic HSV shedding among women on highly active antiretroviral therapy Presented by Joseph Harwell, United States (TBC) Harwell J.1, Cu-Uvin S.1, DeLong A.2, Hogan J.2, Burtwell H.1, Ingersoll J.3, Moreira C.1, Chapman S.1, Kurpewski J.1, Cerezo J.1, Caliendo A.3 1Brown Medical School, Infectious Diseases, Providence, United States, 2Brown University, Statistical Sciences, Providence, United States, 3Emory University, Clinical Pathology, Atlanta, United States
TUPEB040 Abstract	Genotypic sensitivity score predicts successful treatment outcomes after supervised HAART in late stage HIV disease Presented by Delivette Castor, United States (TBC) Castor D.1, Vlahov D.2, Hoover D.3, Berkman A.4, Wu Y.F.2, Zeller B.5, Brechtl J.6, Hammer S.7 1Rockefeller University, Aaron Diamond AIDS Research Center, NY, United States, 2New York Academy of Medicine, Center for Urban Epidemiologic Studies, NY, United States, 3Rutgers, The State University of New Jersey, Statistics, Piscataway, United States, 4Columbia University, Epidemiology, NY, United States, 5H.E.L.P / Project Samaritan Services Inc, Bronx, United States, 6Terence Cardinal Cook, NY, United States, 7Columbia University, NY, United States
TUPEB052 Abstract	Genotyping the HIV-1 pol gene: an effective tool for determining subtype and drug resistant patterns among transmitting mothers in a PMTCT cohort in Jos, Nigeria Presented by Alash'le Abimiku, United States (TBC) Lar P.1, Lar N.2, Bermis K.3, Jelpe D.4, Larry A.5, Zella D.3, Blattner W.3, Kanki P.6, Carr J.3, Abimiku A.3 1University of Jos, Microbiology, Jos, Nigeria, 2Plateau State Specialist Hospital, O&G, Jos, Nigeria, 3School of Medicine, University of Maryland, Institute of Human Virology, Baltimore, United States, 4Plateau State Specialist Hospital, PLSVIREC, Jos, Nigeria, 5Plateau State Specialist Hospital, Jos, Nigeria, 6Harvard School of Public Health, Epidemiology and Immunology, Boston, United States
TUPEB138 Abstract	Growth rates and dietary intakes of macro- and micronutrient among HIV infected children Presented by Supaporn Pengnonyang, Thailand Pengnonyang S.1, Chaturawit C.1, Phanuphak N.1, Petroni N.2, Sadler S.3, Musson R.3, Winichagoon P.4, Wasantvisut E.4, Gold J.3, Phanuphak P.1 1The Thai Red Cross AIDS Research Centre, Bangkok, Thailand, 2John Hopkins University, Bloomberg School of Public Health, Baltimore, United States, 3Albion Street Centre, Sydney, Australia, 4Institute Nutrition, Mahidol University, Bangkok, Thailand
TUPEB064 Abstract	HAART is not independently associated with the presence of significant coronary stenosis in African Americans in the US Presented by Shenghan Lai, United States (TBC) Lai S.1 1Johns Hopkins School of Medicine, Pathology, Baltimore, United States
TUPEC014 Abstract	Health care facility assessments for sexualy transmitted diseases Presented by Praneeta Varma, India (TBC) Varma P.1 1APAC - VHS - USAID, Programs support, Chennai, India
TUPEA013 Abstract	Highly restricted T cell receptor repertoire against an immunodominant HIV-1 CTL epitope with a stereotypic amino acid substitution Presented by AI KAWANA-TACHIKAWA, Japan (TBC) Kawana-Tachikawa A.1, Miyazaki E.1, Tomizawa M.1, Odawara T.1, Iwamoto A.1 1Advanced Clinical Center, the Institute of Medical Science, the University of Tokyo, Division of Infectious Diseases, Tokyo, Japan
TUPEB142 Abstract	HIV disclosure in HIV positive Thai children Presented by Oratai Butterworth, Thailand (TBC) Butterworth O.1, Bunupuradah T.1, Mengthaisong T.1, Sakornjun W.1, Ananworanich J.2, Pancharoen C.3, Intasan J.1, Najai S.1, Ubolyam S.1, Ruxrungtham K.1, Puthanakit T.1, and the HIV-NAT Pediatric Study Team 1The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand, 2HIV-NAT and South East Asia Research Collaboration with Hawaii (SEARCH), Bangkok, Thailand, 3Chulalongkorn University, Bangkok, Thailand
TUPEB114 Abstract	HIV infection is an independent risk factor for preterm delivery Presented by Oriol Coll, Spain Lopez M.1, Figueras F.1, Hernandez S.1, Pascual J.1, Gonce A.1, Palacio M.1, Lonca M.2, Coll O.1 1Hospital Clinic, Maternal Fetal Medicine, Barcelona, Spain, 2Hospital Clinic, Infectious Diseases, Barcelona, Spain
TUPEA058 Abstract	HIV infection of T cells enhances production of proteins associated with cardiovascular and other metabolic disorders Presented by Suraiya Rasheed, United States (TBC) Rasheed S.1, Hussain A.1, Yan J.1, Chan L.S.2 1Keck School of Medicine, University of Southern California, Laboratory of Viral Oncology, AIDS and Proteomics Research Pathology Department, Los Angeles, United States, 2Keck School of Medicine, University of Southern California, Department of Pediatrics, Los Angeles, United States
TUPEA027 Abstract	HIV subtypes and HIV-specific T cell immunity across the entire HIV genome in Chinese man who has sex with man Presented by Xiaoyan Zhang, China (TBC) Zhang X.1, Huang X.1, Xu J.1, Li S.1, Jiang S.2, Zhang X.2, Li D.2, Ruan Y.1, Xing H.1, Shao Y.1 1State Key Laboratory for Infectious Diseases Prevention and Control,Chinese National Center for AIDS/STD Control and Prevention, Beijing, China, 2Chaoyang District CDC, Beijing, China
TUPEC030 Abstract	HIV suppression and pregnancy outcome with HAART in a cohort of pregnant women in Rio de Janeiro, Brazil Presented by Elizabeth S Machado, Brazil (TBC) Machado E.S.1, Hofer C.1, Costa T.2, Nogueira S.3 1Programa de Assistência Integral à Gestante HIV Positive, Universidade Federal do Rio de Janeiro, Departamento de Medicina Preventiva, Rio de Janeiro, Brazil, 2Programa de Assistência Integral à Gestante HIV Positive, Universidade Federal do Rio de Janeiro, Instituto de Pediatria e Puericultua Martagão Gesteira, Rio de Janeiro, Brazil, 3Secretaria Municipal de Saúde e Faculdade de Medicina, Universidade Católica de Petrópolis, Petrópolis, Brazil
TUPEA041 Abstract	HIV-1 infection and human beta-defensin 2 secretion in a colorectal explant model Presented by Ian McGowan, United States (TBC) Andrews K.1, Anton P.1, Elliot J.1, Adler A.1, McGowan I.1 1David Geffen School of Medicine at UCLA, Center for Prevention Research, Los Angeles, United States
TUPEB033 Abstract	HIV-1 NNRTI mutation profiles in clinical practice: implications for TMC125 use Presented by Laurent COTTE, France (TBC) Cotte L.1, Trabaud M.-A.2, Tardy J.-C.2, Lebouche B.1, Icard V.2, Miailhes P.1, Trepo C.1, Andre P.2 1Hotel-Dieu Hospital, Hepatology/AIDS Unit, Lyon, France, 2Groupe Hospitalier Nord, Virology Laboratory, Lyon, France
TUPEB036 Abstract	HIV-1 protease mutation L76V enhances susceptibility to atazanavir and saquinavir in multidrug-resistant HIV-1 infected patients Presented by Heribert Knechten, Germany (TBC) Braun P.1, Wiesmann F.1, Walter H.2, Däumer M.3, Ehret R.1, Korn K.2, Kaiser R.3, Thiele B.4, Berg T.5, Stürmer M.6, Knechten H.1 1PZB Aachen, Aachen, Germany, 2University of Erlangen, Erlangen, Germany, 3University of Cologne, Cologne, Germany, 4Institute of Immunology, Kaiserslautern, Germany, 5MedLab Berlin, Berlin, Germany, 6University of Frankfurt, Frankfurt, Germany
TUPEB109 Abstract	HIV-1 resistance associated mutations was not selected in women subjected to a prophylaxis for mother-to-child transmission with short-term antiretroviral therapy (START) Presented by Ricardo Sobhie Diaz, Brazil Palacios R.1, Sucupira M.C.A.1, Fusuma E.E.1, Denadai Sanchez A.C.1, Teixeira D.1, Senise J.1, Castelo A.1, Diaz R.S.1, Multidisciplinary Group for Infectious Diseases on Pregnancy - NUPAIG - Hospital São Paulo 1UNIFESP, Division of Infectious Diseases, São Paulo, Brazil
TUPEA036 Abstract	HIV-1 synergistically enhances interferon-γ-induced expression of IP-10: implications for HIV-dementia Presented by Shilpa Buch, United States (TBC) Buch S.1, Dhillon N.1, Peng F.1 1Kansas University Medical Center, Molecular & Integrative Physiology, Kansas City, United States
TUPEB058 Abstract	HIV-2 infection in Spain Presented by Carlos Toro, Spain Toro C.1, Rodes B.1, Aguilera A.2, Caballero E.3, Rodríguez C.4, Tuset C.5, Ortiz de Lejarazu R.6, Eiros J.6, Calderón E.7, Rodríguez-Iglesias M.7, Santana E.8, Benito R.9, Álvarez P.10, García J.11, Gómez-Hernando C.12, Dronda F.13, Amor A.14, Soriano V.1, HIV-2 Spanish Study Group 1Hospital Carlos III, Infectious Diseases, Madrid, Spain, 2Complexo Hospitalario Universitario, Microbiology, Santiago, Spain, 3Hospital Vall d'Hebron, Microbiology, Barcelona, Spain, 4Centro Sandoval, Madrid, Spain, 5Hospital General Universitario, Clinical Analyses, Valencia, Spain, 6Hospital Clínico, Microbiology, Valladolid, Spain, 7Hospital Virgen del Rocío, Internal Medicine, Seville, Spain, 8Hospital Universitario Insular, Microbiology, Las Palmas, Spain, 9Hospital Universitario Lozano Blesa, Microbiology, Zaragoza, Spain, 10Complejo Hospitalario, Microbiology, Pontevedra, Spain, 11Hospital Cristal-Piñor, Microbiology, Orense, Spain, 12Hospital Virgen de la Salud, Microbiology, Toledo, Spain, 13Hospital Ramón y Cajal, Infectious Diseases, Madrid, Spain, 14Hospital Carlos III, Microbiology, Madrid, Spain
TUPEA008 Abstract	Identification of M13 phage displayed V3 loop mimotopes as markers of broad cross-neutralizing plasma of HIV-1 infected individuals Presented by Tessa Dieltjens, Belgium (TBC) Dieltjens T.1, Willems B.1, Coppens S.1, Humbert M.2, Dietrich U.3, Vanham G.1, Janssens W.1 1Institute of Tropical Medicine, Department of Microbiology, Antwerp, Belgium, 2Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States, 3Georg-Speyer-Haus, Frankfurt, Germany
TUPEB129 Abstract	Immunological and virological outcome of pediatric HAART cohort in Phnom Penh, Cambodia Presented by Vibol Ung, Cambodia (TBC) Ung V.1, Marcy O.2, Sam S.1, Chan B.1, Horm S.V.3, Huot C.1, Tran Minh T.4, Courpotin C.4, Nerrienet E.3, Chhour Y.M.5, Mattei J.-F.4 1National Pediatric Hospital, Child Health Improvement Clinic, Phnom Penh, Cambodia, 2French Red Cross, Phnom Penh, Cambodia, 3Institut Pasteur du Cambodge, HIV/Hepatitis Laboratory, Phnom Penh, Cambodia, 4French Red Cross, Paris, France, 5National Pediatric Hospital, Phnom Penh, Cambodia
TUPEB131 Abstract	Immunological recovery in children starting NNRTI-based HAART in a resource limited setting Presented by Stephen Kerr, Thailand (TBC) Puthanakit T.1, Kerr S.2, Ananworanich J.3, Bunupuradah T.2, Boonrak P.2, Butterworth O.2, Srisanthana V.4 1Chiang Mai University, Research Institute for Health Sciences, Chiang Mai, Thailand, 2HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand, 3South East Asia Research Collaboration with Hawaii (SEARCH), Bangkok, Thailand, 4Chiang Mai University Faculty of Medicine, Department of Pediatrics, Chiang Mai, Thailand
TUPEA017 Abstract	Immunomodulation of dendritic cells for enhanced activation of anti-HIV-1 CD8 T cell immunity Presented by Xiaoli Huang, United States (TBC) Huang X.1, Fan Z.1, Kalinski P.2, Borowski L.1, Rinaldo C.1 1University of Pittsburgh, GSPH, Infectious Diseases and Microbiology, Pittsburgh, PA, United States, 2University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
TUPEA062 Abstract	Impact of antiretroviral therapie (ART) during SIVmac251 acute infection in macaques on viral reservoir dynamics Presented by Pierre Roques, France (TBC) Roques P.1, Sellier P.1, Mannioui A.1, Bourry O.1, Peruchon S.1, Dereuddre-Bosquet N.2, Le Tortorec A.3, Delache B.1, Brochard P.1, Calvo J.1, Richard-Clausse Y.4, Dejuck-Rainsford N.3, Prevot S.5, Le Grand R.1 1IMETI/DSV/CEA, Service d’Immuno-Virologie, Fontenay aux Roses, France, 2SpiBio, Virologie, Fontenay aux Roses, France, 3INSERM U625, GERHM, Rennes, France, 4IMETI/DSV/CEA, Service d'Immuno-Virologie, Fontenay aux Roses, France, 5Hôpital Antoine Béclère / AP-HP, Service d’Anatomo-pathologie, Clamart, France
TUPEA040 Abstract	Impact of co-infection on racial differences in genital antibody dependent cell-mediated cytotoxicity (ADCC) against HIV Presented by Linda L. Baum, United States (TBC) Nag P.1, Neems L.1, Kim J.1, Iwema J.2, Landay A.L.2, Cohen M.H.3, Baum L.L.2 1Rosalind Franklin University, Microbiology and Immunology, North Chicago, United States, 2Rush University Medical Center, Immunology/Microbiology, Chicago, United States, 3CORE Center of the Cook County Bureau of Health Services and Stroger Hospital, Medicine, Chicago, United States
TUPEB110 Abstract	Impact of HAART on reducing mortality of HIV+ pregnant women (PW) with advanced HIV disease in the setting of PMTCT Presented by Adias Marcelin, Haiti (TBC) Deschamps M.M.1, Bonhomme J.1, Marcelin A.1, Cleophat J.1, Theodore H.1, Collins M.1, Koening S.P.1, Pape J.W.1 1GHESKIO Centers, Infectious Diseases/HIV Unit, Port-au-Prince, Haiti
TUPEC033 Abstract	Impact of prevention of mother-to-child-transmission of HIV-1 program in Honduras and Belize Presented by Wendy Elizabeth Murillo Barahora, Honduras (TBC) Lorenzana I.1, Murillo Barahora W.E.1 1Universidad Nacional Autonoma de Honduras, Microbiology, Tegucigalpa, Honduras
TUPEB106 Abstract	Implementation of a successful programme for prevention of mother-to-child transmission (PMTCT) at a busy national referral and teaching hospital in Kampala, Uganda Presented by Joyce Matovu Namale, Uganda (TBC) Matovu Namale J.1, Namukwaya Z.1, Mubiru M.1, Musoke P.1, Fowler M.G.1, Ssebaggala J.1, Guay L.2, Mmiro F.1 1MU-JHU Research Collaboration, Kampala, Uganda, 2Johns Hopkins Medical Institute, Baltimore, United States
TUPEC040 Abstract	Implementing prevention strategies of HIV-1 mother to child transmission in post-conflict context: Rwanda’s experience, 2001-2005 Presented by Maurice Bucagu, Rwanda (TBC) Bucagu M.1 1National University of Rwanda, School of Public Health, Kigali, Rwanda
TUPEB141 Abstract	Improving treatment compliance in HIV infected children Presented by Geneviève Vaudre, France (TBC) Vaudre G.1, Dollfus C.1, Tabone M.D.1, Leverger G.1 1Hopital d'enfants Armand Trousseau, Hematologie oncologie pédiatrique, Paris, France
TUPEB102 Abstract	Increased expression of CD8 T cell specific activation markers in the pregnant women with HIV-1 infection Presented by Deshratn Asthana, United States Sachdeva N.1, Oshima K.2, Ashman M.1, Davilla L.1, Okazaki T.2, Inaba N.2, Cotter A.1, Asthana D.1 1University of Miami-Miller School of Medicine, Miami, United States, 2Dokyo University School of Medicine, Tochigi, Japan
TUPEA083 Abstract	Increased immune responses by DNA vaccination in combination with electroporation Presented by George Pavlakis, United States (TBC) Pavlakis G.1, von Gegerfelt A.1, Bergamaschi C.1, Jalah R.1, Rosati M.1, Valentin A.1, Kulkarni V.1, Alicea C.1, Patel V.1, Khan A.2, Draghia-Akli R.2, Weiss D.3, Treece J.3, Pal R.3, Markham P.3, Weiner D.4, Boyer J.4, Egan M.5, Sidhu M.5, Eldridge J.5, Felber B.1 1National Cancer Institute at Frederick, Center for Cancer Research, Frederick, United States, 2AdViSYS, Inc., The Woodlands, United States, 3Advanced BioScience Laboratories, Inc., Kensington, United States, 4University of Pennsylvania School of Medicine, Philadelphia, United States, 5Wyeth Vaccines, Pearl River, United States
TUPEB113 Abstract	Increased incidence of spontaneous abortion during first trimester exposure to efavirenz Presented by Esau Joao, Brazil (TBC) Joao E.1, Calvet G.1, Sidi L.1, Cruz L.1, Cardoso C.1, Cunha C.1, Silva R.1, d´Ippolito M.1, Menezes J.1 1Hospital dos Servidores do Estado, Infectious Diseases Department, Rio de Janeiro, Brazil
TUPEB007 Abstract	Increasing partner involvement in antenatal care settings: comparing two approaches Presented by Isabelle Yersin, Mozambique Yersin I.1, Adriano H.1, Langa J.1, Langa M.2, Rurane O.2, Langa O.2, Langa G.3, Oliveira-Tsiouris F.4, Trottier D.3 1International Center for AIDS Care and Treatment Programs (ICAP), Mailman School of Public Health, Columbia University Maputo, PMTCT, Maputo, Mozambique, 2Jose Macamo Health Center, Maputo, Mozambique, 3International Center for AIDS Care and Treatment Programs (ICAP), Mailman School of Public Health, Columbia University Maputo, Maputo, Mozambique, 4International Center for AIDS Care and Treatment Programs (ICAP), Mailman School of Public Health, Columbia University, New York, United States
TUPEA045 Abstract	Interleukin-2 and zoledronate combined treatment induces both innate and adaptive immunity in HIV-infected persons Presented by Gianpiero D'Offizi, Italy (TBC) Poccia F.1, Gioia C.1, Sacchi A.1, Agrati C.1, Martini F.1, Bellagamba R.2, Abdeddaim A.2, Malkowsky M.3, Capobianchi M.R.4, Vlassi C.2, Narciso P.2, Amendola A.4, Abbate I.4, D'Offizi G.2 1Natl.Inst.for Infect. Diseases L.Spallanzani, Cellular Immunology Lab., Rome, Italy, 2Natl.Inst.for Infect. Diseases L.Spallanzani, Clinical Department, Rome, Italy, 3University of Wisconsin Medical School, Madison, United States, 4Natl.Inst.for Infect. Diseases L.Spallanzani, Virology Lab., Rome, Italy
TUPEA028 Abstract	Is it possible to enhance the activation of the human immunodeficiency virus (HIV)-specific CD8+ T cells by histamine? Presented by Dalibor Sedlacek, Czech Republic (TBC) Sedlacek D.1, Hanzlikova J.2, Liska M.2, Gorcikova J.2, Panzner P.2, Amiramini S.1 1University Hospital, Dept. of Infectious Diseases, Plzen, Czech Republic, 2University Hospital, Dept. Immunology and Allergology, Plzen, Czech Republic
TUPEC016 Abstract	Knowledge about symptoms and modes of transmission of common sexually transmitted infections (STI) in German men who have sex with men (MSM) Presented by Ulrich Marcus, Germany (TBC) Marcus U.1, Schmidt A.J.2, Hamouda O.1 1Robert Koch-Institut, Infectious Disease Epidemiology, Berlin, Germany, 2Wissenschaftszentrum Berlin (WZB) für Sozialwissenschaften, Public Health Research Group, Berlin, Germany
TUPEB086 Abstract	Lack of mitochondrial toxicity in adipose tissue from HIV-infected women as measured at delivery: results from the Italian prospective cohort on antiretroviral therapy in pregnancy: efficacy and toxicity (TARGET) study Presented by Andrea Cossarizza, Italy (TBC) Nasi M.1, Chiesa E.2, Rocco G.1, Sabbatini F.3, Mussini C.3, Fiore S.4, Ferrazzi E.4, Palai N.5, Campatelli C.6, Ravagni F.7, Tibaldi C.8, D'Arminio Monforte A.9, Cossarizza A.1 1University of Modena and Reggio Emilia, Department of Biomedical Sciences, Modena, Italy, 2Busto Arsizio Hospital, Busto Arsizio, Varese, Italy, 3Clinic of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Modena, Italy, 4L Sacco Hospital, University of Milano, Clinic of Obstetrics and Gynecology, Milano, Italy, 5University of Brescia, Department of Obstetrics and Gynecology, Brescia, Italy, 6S.Annunziata Hospital, Unit of Obstetrics and Gynecology, Firenze, Italy, 7University of Pavia, Clinic of Obstetrics and Gynecology, Pavia, Italy, 8University of Torino, Department of Obstetrics and Gynecology, Torino, Italy, 9Clinic of Infectious and Tropical Diseases, San Paolo Hospital, University of Milano, Milano, Italy
TUPEC015 Abstract	Legalizing and regulating commercial sex workers to decrease HIV transmission Presented by Dennis Fuller, United States Reilly T.1, Fuller D.2, Cade J.3, Reich R.4 1Univ of NV Las Vegas, Public Administration, Las Vegas, United States, 2Nevada AIDS Research and Education Society, Clinical Research, Las Vegas, United States, 3Univ of NV School of Medicine, Internal Medicine, Las Vegas, United States, 4Nevada AIDS Research and Education Society, Behavioral Research, Las Vegas, United States
TUPEB127 Abstract	Long-term effectiveness of NNRTI-based HAART in antiretroviral-naive HIV-infected children participating in Thailand´s National Access Program: 192-week result Presented by Peninnah Oberdorfer, Thailand Aurpibul L.1, Puthanakit T.1, Oberdorfer P.2, Akarathum N.3, Kanjanavanit S.4, Wannarit P.5, Sirisanthana T.1, Sirisanthana V.6 1Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand, 2Faculty of Medicine, Chiang Mai University, Department of Pediatrics, Chiang Mai, Thailand, 3Sanpathong hospital, Chiang Mai, Thailand, 4Nakorn Ping hospital, Chiang Mai, Thailand, 5Lamphun hospital, Lamphun, Thailand, 6Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
TUPEB087 Abstract	Long-Term subcutaneous tissue changes among antiretroviral naïve persons initiating three different nucleoside regimens Presented by Carl Grunfeld, United States Shlay J.1, Sharma S.2, Bartsch G.2, Peng G.2, Gibert C.3, Grunfeld C.4 1Denver Community Program for Clinical Research on AIDS, University of Colorado Health Sciences Center, Denver, United States, 2CPCRA Statistical and Data Management Center, University of Minnesota, Minneapolis, United States, 3Wide-Reaching AIDS Program, Veterans Affairs Medical Center, Washington, DC, United States, 4Veterans Affairs Medical Center and University of California, San Francisco, United States
TUPEB004 Abstract	Low CD4 T cell counts in sub-Saharan African subjects enrolled at the time of HIV-1 primary infection in the French ANRS PRIMO cohort Presented by Cécile Goujard, France (TBC) Meyer L.1, Chaix M.-L.2, Nagy Z.3, Venet A.4, Deveau C.3, Pacanovski J.5, Delfraissy J.-F.6, Rouzioux C.7, Sinet M.4, Goujard C.6, for the ANRS PRIMO Study Group 1Hopital Bicêtre, AP-HP, INSERM U822, Service de Santé Publique, Le Kremlin Bicetre, France, 2Hopital Necker, AP-HP, EA MRT 3620, Paris, France, 3INSERM U822, Service de Santé Publique, Le Kremlin Bicetre, France, 4INSERM U802, and Faculté de Medecine Paris Sud, Le Kremlin Bicetre, France, 5Hopital Saint Antoine , AP-HP, Paris, France, 6Hopital Bicetre, AP-HP, and Faculté de Medecine Paris Sud, INSERM U802, Internal Medicine Unit, Le Kremlin Bicetre, France, 72, Paris, France
TUPEC028 Abstract	Low emergence of nevirapine (NVP) and lamivudine (3TC) resistance after post-partum interruption of a triple drug regimen for prevention of HIV mother to child transmission (MTCT) Presented by Héctor Pérez, Argentina (TBC) Pérez H.1, Vignoles M.2, Laufer N.1, Gómez A.2, Coll P.1, Lattner J.1, Rolón M.J.1, Salomón H.2, Cahn P.1 1Hospital Juan A Fernández, Infectious Diseases Unit, Buenos Aires, Argentina, 2Argentinean National Reference Center for AIDS, Microbiology Department, University of Buenos Aires, Buenos Aires, Argentina
TUPEB074 Abstract	Lower prevalence of small, dense low-density lipoprotein (sd-LDL) in hypertriglyceridemic HIV-infected patients than in non-HIV-infected subjects Presented by Andreas Trein, Germany (TBC) Trein A.1, Schnaitmann E.1, Richter W.2 1HIV Center, Stuttgart, Germany, 2Institute for Lipid Metabolism, Munich/Windach, Germany
TUPEC034 Abstract	Male partners´ response to HIV prevention and treatment services provided through antenatal care in Kano Presented by Abdulrazak H. Yahaya, Nigeria (TBC) Yahaya A.H.1, Ibrahim U. F.1, Sadisu M. N.1, Ibrahim M. A.1, Umar I.S.1, Saleh K A.2, Mikahil T. H.3, Ado M.S.4, Sani F. A.1, Ado M.A.5, Abubakar M.6 1Murtala Muhammad Specialist Hospital, HIV/Immunology Laboratory, Pathology, Kano, Nigeria, 2Murtala Muhammad Specialist Hospital, Microbiology Laboratory, Pathology, Kano, Nigeria, 3GHAIN office, MSD, Kano, Nigeria, 4Murtala Muhammad Specialist Hospital, Pathology, Kano, Nigeria, 5Murtala Muhammad Specialist Hospital, Blood Bank Laboratory, Kano, Nigeria, 6Murtala Muhammad Specialist Hospital, Chemical Pathology Laboratory, Pathology, Kano, Nigeria
TUPEA025 Abstract	Mapping and cross-clade evaluation of Nef-specific cellular immune responses in HIV-1+ individuals reveal breadth underestimation and discrepant patterns of T cell functionality Presented by Gabriela Turk, Argentina (TBC) Turk G.1, Gherardi M.M.1, Laufer N.2, Cahn P.2, Cox J.3, Salomon H.1 1National Reference Center for AIDS, University of Buenos Aires, Buenos Aires, Argentina, 2Hospital Fernandez, Buenos Aires, Argentina, 3Walter Reed Army Institute of Research/US Military HIV Research Program, Rockville, United States
TUPEC046 Abstract	Men´s knowledge of prevention of mother to child transmission (PMTCT) in rural Tanzania Presented by Michael Burke, Australia (TBC) Burke M.1, Rajabu M.2, Kippax S.3, Crawford J.3, Kaldor J.4 1UNSW (University of New South Wales), NCHSR (National Centre for HIV Social Research), NCHSR (National Centre for HIV Social Research, NCHECR (National Centre in HIV Epidemiology and Clinical Research), Sydney, Australia, 2Teule Hospital, Muheza, Tanzania, United Republic of, 3UNSW, NCHSR, Sydney, Australia, 4UNSW, NCHECR, Sydney, Australia
TUPEB071 Abstract	Metabolic results in the Simplification LOpinavir to ATazanavir Trial (SLOAT) Presented by Germán Ramírez-Olivencia, Spain (TBC) Ramírez-Olivencia G.1, Ruiz-Sancho A.1, Martín-Carbonero L.1, González-Lahoz J.1, Soriano V.1 1Hospital Carlos III, Infectious Diseases, Madrid, Spain
TUPEB118 Abstract	Microtransfusion and viral exposure in uninfected infants born to HIV-infected women Presented by Julia Warning, Australia (TBC) Warning J.1, Ziegler J.1, Ffrench R.2 1University of New South Wales, School of Women's and Children's Health, Randwick, Australia, 2Burnet Institute, Viral Immunology Group, Melbourne, Australia
TUPEA044 Abstract	Minocycline alters CD4+ T cell physiology and decreases HIV reactivation from latency Presented by Gregory Szeto, United States (TBC) Szeto G.1, Barber S.1, Siliciano R.2, Clements J.1 1Johns Hopkins University School of Medicine, Department of Molecular and Comparative Pathobiology, Baltimore, United States, 2Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, United States
TUPEA031 Abstract	Modulation of HIV-1 replication by the Th2 chemokine CCL18 Presented by Helena Schmidtmayerova, United States (TBC) Schmidtmayerova H.1, Singh P.1, Chaung W.1, Giannakou A.1, Pompucci L.1, Malhotra P.2 1The Feinstein Institute for Medical Research, Manhasset, United States, 2North Shore University Hospital, Manhasset, United States
TUPEC044 Abstract	Monitoring system for the prevention of mother to child transmission (PMTCT) program in resource limited settings: the Affixe-PMTCT model from Cameroon Presented by . Tchendje, Cameroon (TBC) Tchendje 1, Tsague L.2, Tchendjou P.3, Bella L.4 1AFFIXE Engineering Co., Yaounde, Cameroon, 2Rollins School of Public Health, Atlanta, United States, 3Centre Pasteur du Cameroun, Yaounde, Cameroon, 4Directorate of Disease Control, Ministry of Public Health, Yaounde, Cameroon
TUPEB116 Abstract	Monitoring the early HIV infant diagnosis program in Tanzania Presented by Harriet Nuwagaba-Biribonwoha, Tanzania, United Republic of (TBC) Nuwagaba-Biribonwoha H.1, Semo B.1, Gonzalez L.F.2, Aziz A.1, Almeida A.1, Gamaliel J.3, Mtunga S.3, Kitogwa C.1, Cunningham A.1, Justman J.4, Abrams E.4 1Columbia University, ICAP, Dar es salaam, Tanzania, United Republic of, 2Columbia University, ICAP, Kigali, Rwanda, 3Columbia University, ICAP, Mwanza, Tanzania, United Republic of, 4Columbia University, ICAP, New York, United States
TUPEA080 Abstract	Monocyte-derived dendritic cells from HIV-1 individuals show impaired functions that is not resolved by anti-retroviral therapy Presented by Sandrine Buisson, United Kingdom (TBC) Buisson S.1, Kelleher P.1, Gotch F.1, Patterson S.1 1Imperial College London, Immunology, London, United Kingdom
TUPEC041 Abstract	Mother to child transmission of HIV at Calmette Hospital, Phnom Penh, Cambodia: benefits of PMTCT national recommendations Presented by Leang Sim Kruy, Cambodia (TBC) Kruy L.S.1, Chham K.1, Im S.1, Keo S.1, Nam C.M.1, Ouv S.H.1, Ouk v.2, Ngin S.3, Segeral O.4, Delfraissy J.F.4, Nerrienet E.3 1Calmette Hospital, Maternity, Phnom Penh, Cambodia, 2Calmette Hospital, Esther/Calmette, Phnom Penh, Cambodia, 3Institut Pasteur du Cambodge, HIV/Hepatitis Laboratory, Phnom Penh, Cambodia, 4CHU de Bicêtre, Paris, France
TUPEC048 Abstract	Mother-to-child-transmission of HIV at Calmette Hospital, Phnom Penh, Cambodia: benefits of PMTCT national recommendations Presented by Chhim Kearena, Cambodia Kruy L.S.1 1Calmette Hospital, Phnom Penh, Cambodia
TUPEA076 Abstract	Mucosal HIV-polyepitope DNA vaccine in suppositories; design and preclinical study Presented by Larisa Karpenko, Russian Federation (TBC) Karpenko L.1, Veremeiko T.A.1, Levagina G.M.1, Danilenko E.D.1, Bazhan S.I.1, Ilyichev A.A.1 1State Research Center of Virology and Biotechnology 'Vector', Department of Immunotherapeutic Drug Development, Novosibirsk, Russian Federation
TUPEB067 Abstract	Myeloperoxidase level does not predict future cardiovascular events in HIV-infected subjects Presented by Dalia El Bejjani, United States (TBC) El Bejjani D.1, Hazen S.2, Mackay W.3, Hulgan T.4, Glass N.4, Tungsiripat M.2, McComsey G.5 1University Hospitals of Cleveland and Case Western Reserve University, Cleveland, United States, 2Cleveland Clinic Foundation, Cleveland, United States, 3Center for AIDS Research of Case Western Reserve University, Cleveland, United States, 4Vanderbilt University School of Medicine, Nashville, United States, 5Rainbow Babies and Children's Hospital and Case Western Reserve University, Cleveland, United States
TUPEA009 Abstract	Natural killer cells and selected enzyme/metabolite profile during HIV infection and clinical progression to AIDS Presented by Ezekiel Onyonka Mecha, Kenya (TBC) Mecha E.O.1, Omwadho C.A.1, Mukuria J.C.1 1University of Nairobi/ University of Washington Colaborative Programme, Paediatrics and Child Health, Nairobi, Kenya
TUPEC020 Abstract	Neisseria gonorrhoeae and chlamydia trachomatis infections in patients attending the STI and the HIV clinics in Barbados Presented by Krishna Kilaru, Barbados (TBC) Kilaru K.1, Kumar A.2, Sippy N.3, Barbados HiV/AIDS Study Group 1Ministry of Health, STI Program, Sir Winston Scott Polyclinic, Saint Michael, Barbados, 2University of the West Indies, School of Clinical Medicine & Research, St. Michael, Barbados, 3Ministry of Health, Ladymeade Reference Unit, St. Michael, Barbados
TUPEA007 Abstract	Neutralization activity of HIV antibodies on Langerhans cells, implication of langerin in infection, and transfer to T cells Presented by Christiane Moog, France Peressin M.1, Holl V.1, Xu K.1, Decoville T.1, Schmidt S.1, Aubertin A.M.1, Moog C.1 1Institute of Virology, U778, Strasbourg, France
TUPEA015 Abstract	NK cell-mediated antibody dependent cellular cytotoxicity (ADCC) against HIV Presented by Amy Chung, Australia (TBC) Chung A.1, Stratov I.1, Rollman E.1, Kent S.1 1University of Melbourne, Department of Microbiology and Immunology, Parkville, Australia
TUPEA043 Abstract	NK cells pulsed by IL-15 decrease p24 production and HIV-DNA in T-CD4+ and PBLs infected cells Presented by Mauro Andreotti, Italy (TBC) Andreotti M.1, d'Ettorre G.2, Zaffiri L.2, Galluzzo C.M.1, Pirillo M.F.1, Amici R.1, Erario L.2, Giuliano M.1, Vella S.1, Mastroianni C.M.2 1Istituto Superiore di Sanità, Drug Research and Evaluation, Rome, Italy, 2University 'La Sapienza', Infectious Disease, Rome, Italy
TUPEB079 Abstract	No change in glucose tolerance with lopinavir/ritonavir (LPV/r) + ZDV/3TC induction followed by LPV/r monotherapy through 96 weeks Presented by Barbara da Silva, United States (TBC) da Silva B.1, King M.1, Dehaan M.1, Wikstrom K.1, Niemi K.1, Hanna G.1 1Abbott Laboratories, Abbott Park, United States
TUPEB097 Abstract	Obstructive Lung Disease (OLD) in an urban cohort of HIV-1 infected persons Presented by Ramanasri Kudipudi, United States (TBC) Kudipudi R.1, Seiden J.1, Debra C.1, Swaminathan S.1, Li J.2, Kim S.3, Fennelly K.1, Hodder S.1 1University of Medicine and Dentistry, Medicine, Newark, United States, 2University Hospital, Newark, United States, 3University of Medicine and Dentistry, Preventive Medicine, Newark, United States
TUPEB070 Abstract	Once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir: 60-week efficacy and metabolic effects Presented by Weerawat Manosuthi, Thailand (TBC) Manosuthi W.1, Chaovavanich A.1, Prasithsirikul W.1, Athichathanabadi C.1, Likanonsakul S.1, Tantisiriwat W.2, Bowonwatanuwong C.3, Chumpathat N.1, Termvises P.1, Sungkanuparph S.4 1Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand, 2Faculty of Medicine, Srinakharinwirot University, Nakornnayok, Thailand, 3Chonburi Hospital, Ministry of Public Health, Chon Buri, Thailand, 4Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
TUPEC024 Abstract	Ongoing HIV transmission among men who have sex with men (MSM) may be driven particularly by incomplete serosorting in already diagnosed HIV positive men, who are not yet on antiretroviral therapy (ART) and have a high incidence of sexually transmitted infection (STIs) Presented by Axel J. Schmidt, Germany Marcus U.1, Schmidt A.J.2, Hamouda O.1 1Robert Koch-Institut, Infectious Disease Epidemiology, Berlin, Germany, 2WZB (Social Science Research Center Berlin), Public Health Unit, Berlin, Germany
TUPEA049 Abstract	Opiate regulation of DARPP-32 in the pathogenesis of HIV encephalopathy Presented by Supriya Mahajan, United States (TBC) Mahajan S.1, Thompson A.2, Aalinkeel R.3, Reynolds J.3, Sykes D.3, Balakrishnan B.3, Pudavur H.4, Schwartz S.A.3 1SUNY@Buffalo, Medicine, Amherst, United States, 2Research Institute on Addictions, Buffalo, United States, 3SUNY@Buffalo, Medicine, Buffalo, United States, 4SUNY@Buffalo, Chemistry, Buffalo, United States
TUPEC031 Abstract	Outcome of care in a MTCT-PLUS model of care in Uganda Presented by Charles Kabugo, Uganda (TBC) Kabugo C.1, Buzaalirwa L.2, Okong P.3, Munduru B.1 1Nsambya HIV Clinic, Kampala, Uganda, 2UPHOLD Uganda, Kampala, Uganda, 3Nsambya HIV Clinic, OBS-Gynae, Kampala, Uganda
TUPEB136 Abstract	Outcomes of tuberculosis co-infected children below 3 years on art in Western Kenya Presented by Winstone Nyandiko-Mokaya, Kenya (TBC) Nyandiko-Mokaya W.1, Mwangi A.2, Arpadi S.3, Ayaya S.1, Nabakwe E.1, Carter J.4 1Moi University/ AMPATH, Pediatrics, Eldoret, Kenya, 2AMPATH, Biostatistics, Eldoret, Kenya, 3Mailman School of public Health, Clinical Pediatrics, NewYork, United States, 4Brown University, Infectious Diseases, Providence, United States
TUPEC043 Abstract	Participation of traditional birth attendants in mother-child health services including prevention of mother to child transmission of HIV: a feasibility study in rural Zimbabwe Presented by Freddy Perez, France (TBC) Perez F.1, Aung D.1, Ndoro T.2, Mugore L.2, Engelsmann B.2, Marangwanda C.3, Dabis F.1 1Institute of Public Health, Epidemiology & Development (ISPED)-University Bordeaux-France, Bordeaux, France, 2ISPED - Zimbabwe, Harare, Zimbabwe, 3Kapneck Trust, Harare, Zimbabwe
TUPEB017 Abstract	Performance of Calypte AWARE HIV-1/2 BSP rapid test (for whole blood) and the AWARE HIV-1/2 OMT (for mouth swabs) in a context of high HIV-1 genetic diversity Presented by Nicaise Ndembi, Uganda Ndembi N.1, Moudourou S.2, Meko S.1, Tayou C.2, Mbanya D.2, Kaptue L.1 1University of Yaounde -I, Hematology and Virology, Yaounde, Cameroon, 2Centre Hospitalier Universitaire (CHU), Laboratoire d'hematologie et transfusion sanguine, Yaounde, Cameroon
TUPEC047 Abstract	Perinatal HIV transmission in Buenos Aires (CABA): looking for new approaches Presented by Adriana Basombrío, Argentina (TBC) Basombrío A.1, Bruno M.1, Duran A.1, Ivalo S.1, Nan M.1, Vila M.1, Vulcano S.1, Bloch C.1, Equipo de Prevención de la Transmisión Vertical del VIH de la Coordinación SIDA de la Secretaría de Salud del Gobierno de la Ciudad de Buenos Aires 1Coordinación SIDA, Gobierno de la CABA, Buenos Aires, Argentina
TUPEA067 Abstract	Peripheral blood lymphocytes and macrophages HIV-1 proviral load as a criteria of successful longterm HAART Presented by Andrey Shemshura, Russian Federation (TBC) Shemshura A.1, Saoukhat S.1, Poddubskaya S.1, Kolpakov D.1, Kucherenko I.1 1Rostov Research Institute of Microbiology and Parasitology, Russian Southern AIDS Centre, Rostov-on-Don, Russian Federation
TUPEB077 Abstract	Persistent reduction in peripheral glucose disposal starting prior to fat distribution changes, only during first line ART with AZT/3TC/LPV/r but not NVP/LPV/r, suggests contribution of AZT/3TC to insulin resistance by a body composition-independent mechanism Presented by Marit G.A. van Vonderen, Netherlands (TBC) van Vonderen M.G.A.1, Blümer R.M.E.2, Hassink E.3, Sutinen J.4, Ackermans M.T.5, van Agtmael M.A.1, Yki-Jarvinen H.6, Danner S.A.1, Sauerwein H.P.2, Reiss P.7, and the MEDICLAS study group. 1VU University Medical Center, Department of Internal Medicine, Amsterdam, Netherlands, 2Academic Medical Center, Department of Endocrinology and metabolism, Amsterdam, Netherlands, 3International Antiviral Therapy Evaluation Center, Amsterdam, Netherlands, 4Helsinki University Central Hospital, Department of Internal Medicine, Helsinki, Finland, 5Academic Medical Center, Department of Clinical chemistry laboratory of endocrinology and radiochemistry, Amsterdam, Netherlands, 6Helsinki University Central Hospital, Division of diabetes, Helsinki, Finland, 7Academic Medical Center, Department of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, Netherlands
TUPEB089 Abstract	Phalangeal quantitative ultrasound (f-QUS): cheaper methods for evaluate bone pathologies in HIV-infected women Presented by Raffaella Rosso, Italy (TBC) Di Biagio A.1, Rosso R.2, Parodi A.3, Torrisi C.3, Nicolini L.2, Delfino E.2, Ginocchio F.2, De Terlizzi F.4, Vignolo M.3, Viscoli C.5 1Infectious Diseases, San Martino Hospital, Genoa, Italy, 2Infectious Diseases, University of Genoa, Genoa, Italy, 3I Pediatric Clinic, University of Genoa, G. Gaslini Institute, Genoa, Italy, 4Medical Office, IGEA s.r.l., Modena, Italy, 5Infectious Diseases, University of Genoa, San Martino Hospital, Genoa, Italy
TUPEB026 Abstract	Phenotypic cut-off values for the clinical interpretation of predicted viral fold change for antiretroviral agents: the vircoTYPE HIV-1 approach Presented by Jorge Villacian, Belgium (TBC) Villacian J.1, Van Craenenbroeck E.1, Winters B.1, Bacheler L.2, Virco Clinical Cut-offs Collaborative Group 1Virco BVBA, Mechelen, Belgium, 2VircoLab Inc, Durham, NC, United States
TUPEA061 Abstract	Phosphoepitope-specific flow cytometry screening reveals HIV-associated deregulation of cytokine-driven Jak-STAT and MAP kinase signaling Presented by Andrew W. Lee, United States (TBC) Lee A.W.1, Sharp E.R.2, Rosenberg M.G.3, Hecht F.M.4, Nolan G.P.5, Nixon D.F.2 1Stanford University School of Medicine, Baxter Laboratory of Genetic Pharmacology, and Division of Infectious Diseases, Stanford, CA, United States, 2UCSF, Department of Experimental Medicine, San Francisco, CA, United States, 3Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, United States, 4UCSF, Department of Medicine, San Francisco, CA, United States, 5Stanford University School of Medicine, Baxter Laboratory of Genetic Pharmacology, Department of Microbiology and Immunology, Stanford, CA, United States
TUPEA037 Abstract	Plasma IL-7 levels do not evolve in parallel to CD4+ counts at early stages of HIV infection Presented by Mariola López, Spain (TBC) Benito J.M.1, López M.1, Lozano S.1, González-Lahoz J.1, Soriano V.1 1Hospital Carlos III, Molecular Biology Laboratory, Madrid, Spain
TUPEC027 Abstract	PMTCT programme in Botswana: estimated number of HIV infections averted between 2002 - 2006 Presented by Koona Keapoletswe, Botswana (TBC) Keapoletswe K.1, Anderson M.G.1, Steen T.W.2, Seipone K.1, Kaisara T.1, de la Hoz Gomez F.1, Mmelesi M.1, Tlale J.1, Moalosi J.1, Mpoyo F.3 1Ministry of Health, HIV/AIDS Prevention and Care, Gaborone, Botswana, 2Ministry of Health, Department of Public Health, Gaborone, Botswana, 3UNICEF, Gaborone, Botswana
TUPEB025 Abstract	Point of care lactate testing predicts mortality in a predominantly HIV-infected patient population with severe sepsis admitted to a national referral hospital in Uganda Presented by Christopher C Moore, United States (TBC) Moore C.C.1, Jacob S.T.1, Pinkerton R.1, Meya D.2, Mayanja-Kizza H.3, Reynolds S.J.4, Scheld W.M.1 1University of Virginia Health System, Department of Medicine, Division of Infectious Diseases and International Health, Charlottesville, Virginia, United States, 2Makerere University, Infectious Diseases Institute, Kampala, Uganda, 3Makerere University, Faculty of Medicine, Kampala, Uganda, 4National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Intramural Research, Bethesda, United States
TUPEA038 Abstract	Polymorphic variants of DC-SIGNR and SDF-1 in HIV-1 patients in North India Presented by kavitha rajsekar, India (TBC) Rajsekar K.1, Chaudhary O.1, Verma R.1, Ahmed I.1, Bhasin R.1, Bala M.1, Luthra K.1 1All India Insititute of Medical Sciences, Biochemistry, New Delhi, India
TUPEC002 Abstract	Pre-coital rectal douching: implications for rectal microbicides Presented by Alex Carballo-Dieguez, United States (TBC) Carballo-Dieguez A.1, Bauermeister J.1, Ventuneac A.1 1Columbia University - HIV Center, New York, NY, United States
TUPEB112 Abstract	Pregnancy and neonatal outcomes of perinatally-infected HIV adolescents and young adults Presented by Shauna Williams, United States (TBC) Williams S.1, Keane M.1, Bettica L.2, Dieudonne A.2, Bardeguez A.1 1UMDNJ-New Jersey Medical School, Obstetrics, Gynecology and Women's Health, Newark, NJ, United States, 2UMDNJ-New Jersey Medical School, Pediatrics, Newark, NJ, United States
TUPEA081 Abstract	Preservation of a subset of SIV-specific CD4+ T cells with central memory markers correlates to control of viremia in SIVmac251 infected macaques Presented by Antonio Valentin, United States (TBC) Valentin A.1, von Gegerfelt A.1, Alicea C.1, Patel V.1, Marthas M.2, Van Rompay K.2, Pavlakis G.1, Felber B.1 1National Cancer Institute at Frederick, Center for Cancer Research, Frederick, United States, 2California National Regional Primate Research Center, Davis, United States
TUPEB073 Abstract	Prevalence and characteristics of patients with low HDL cholesterol (HDLc) Presented by Enrique Bernal, Spain (TBC) Bernal E.1, Masia M.1, Padilla S.1, Ramos J.M.1, Escolano C.1, Piedecausa M.2, Martín-Hidalgo A.2, Gutierrez F.1 1Hospital General Universitario de Elche, Unidad de Enfermedades Infecciosas, Elche, Spain, 2Hospital General Universitario de Elche, Unidad Riesgo Vascular, Servicio de Medina Interna, Elche, Spain
TUPEB137 Abstract	Prevalence of anemia and impact of iron status in HIV infected children with moderate immunosuppression Presented by Torsak Bunupuradah, Thailand Kosalaraksa P.1, Engchanil C.1, Puthanakit T.2, Ananworanich J.2, Bunupuradah T.2, Luesomboon W.3, Vibol U.4, Sopa B.2, Intasan J.2, Jupimai T.2, Hirunwadee N.2, Waraporn S.2, Lumbiganon P.1, Ruxrungtham K.2, The PREDICT study group 1Department of Pediatrics,Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, 2HIV-NAT, The Thai Red Cross AIDS Research Center, Bangkok, Thailand, 3Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, 4National Pediatric Hospital, Phnom Penh, Cambodia
TUPEB135 Abstract	Prevalence of cryptosporidium infection and related risk factors in children with or without diarrhoea in northern part of Tanzania Presented by Blandina Theophil Mmbaga, Tanzania, United Republic of (TBC) Mmbaga B.T.1, Kinabo G.D.1, Swai M.1, Shao J.1, Mchele J.2, Henderikx M.3, Houpt E.4, Tolboom J.5, Schimana W.6 1Kilimanjaro Christian Medical Centre, Kilimanajro Christian Medical- College, Tumaini University, Moshi, Kilimanjaro, Tanzania, United Republic of, 2Biotechnology Research Laboratory, KCMC, Kilimanjaro, Tanzania, United Republic of, 3Microbiology Laboratory, Enschede, Netherlands, 4Virginia University, Virginia, United States, 5St. Raboud University, Nimegen, Netherlands, 6Kilimanajro Christian Medical Centre and Elizabeth Glacer paediatric AIDS Foundation, Kilimanjaro, Tanzania, United Republic of
TUPEC022 Abstract	Prevalence of HIV and other sexually transmitted infections in relation to lemon/lime juice douching among female sex workers in Jos, North Central Nigeria Presented by Godwin Imade, Nigeria (TBC) Imade G.1, Sagay A.1, Egah D.2, Onwuliri V.3, Grigg M.4, Egbodo C.1, Thacher T.5, Potts M.6, Short R.4 1University of Jos/Jos University Teaching Hospital, Dept of Obstetrics and Gynaecology, Jos, Nigeria, 2University of Jos/Jos University Teaching Hospital, Dept of Medical Microbiology, Jos, Nigeria, 3University of Jos, Dept of Biochemistry, Jos, Nigeria, 4University of Melbourne, Faculty of Medicine, Melbourne, Australia, 5Jos University Teaching Hospital, Dept of Family Medicine, Jos, Nigeria, 6University of California, School of Public Health, Berkeley, Calfornia, United States
TUPEB041 Abstract	Prevalence of transmitted HIV drug resistance in Botswana: lessons learned from the HIVDR-TS conducted during the 2005 Botswana sentinel survey Presented by Florindo de la Hoz Omez, Botswana (TBC) Bussmann H.1, de la Hoz Omez F.2, Roels T.H.3, Gaseitsiwe S.1, Diphoko E.T.1, Bodika S.M.3, Novitsky V.4, Moyo S.1, Wester W.C.1, Negussie T.3, Seipone K.2, Makhema J.1, Kassim S.3, Davis M.3, Essex M.4 1Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana, 2Minstry of Health, HIV/AIDS Prevention and Care, Gaborone, Botswana, 3BOTUSA Project, a Collaboration between the Government of Botswana and the U.S. Centers for Disease Control and Prevention, Gaborone, Botswana, 4Harvard School of Public Health, Boston MA, USA; Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana
TUPEC035 Abstract	Prevention of mother-to-child transmission: analogy on evolution and impact in Democratic Republic of Congo and Rwanda Presented by Carole Schirvel, Belgium (TBC) Schirvel C.1, Bucagu M.2, Tshingani A.1, Mboyo Nkoso A.3, Mukalay wa Mukalay A.4, Donnen P.1 1Université Libre de Bruxelles, Ecole de Santé Publique, Bruxelles, Belgium, 2Université du Rwanda, Ecole de santé Publique, Butare, Rwanda, 3Programme National Multisectoriel de lutte contre le SIDA, Kinshasa, Congo, the Democratic Republic of the, 4Université de Lubumbashi, Ecole de Santé Publique, Lubumbashi, Congo, the Democratic Republic of the
TUPEC042 Abstract	Prevention of parent-to-child transmission (PPTCT) programme data Vs HIV sentinel surveillance data Presented by Jayashree Muralidharan, India (TBC) Muralidharan J.1, Murugesan J.1, Pandurangan S.1, Navamani P.1, Sahu S.1 1Tamil Nadu State AIDS Control Society, Health & Family Welfare Department, Chennai, India
TUPEB051 Abstract	Primary HIV drug resistance in China, 2004-2005 Presented by Lingjie Liao, China (TBC) Liao L.1, Xing H.1, Cheng H.1, Li X.1, Shang H.2, Li J.3, Zhong P.4, Shao Y.1 1Division of Virology and Immunology, NCAIDS, China CDC, Beijing, China, 2China Medical Univisity, Shenyang, China, 3Chinese Military HIV Test Center, Beijing, China, 4Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China
TUPEC012 Abstract	Primary HIV infection in patients presenting with conventional sexually transmitted infections (STIs) in Ethiopia: magnitude and risk factors Presented by Asaminew Girma, Ethiopia (TBC) Girma A.1, Betre M.1, Wolday D.1, Meles H.1, Geyid A.1, Abebe A.1, Messele T.1 1Addis Ababa Univesity/Facultiy of Medicine, Department of Community Health, Addis Ababa, Ethiopia
TUPEB002 Abstract	Primary infection syndrome is associated with higher viral load and CD8+ T cell counts at the initial phase, but not with early CD4+ T cell loss Presented by Esper Kallas, Brazil Sauer M.M.1, Tomiyama H.Y.1, Bassichetto K.C.2, Oliveira S.M.3, Palacios R.G.1, Kallas E.G.1 1Federal University of São Paulo, São Paulo, Brazil, 2Public Health Department of São Paulo, São Paulo, Brazil, 3Henfil Counselig Testing Center, São Paulo, Brazil
TUPEA073 Abstract	Production of therapeutic HIV-1 vaccine by stable producer cell line for phase I clinical trial Presented by Frank Tung, United States (TBC) Tung F.1, Sciascia-Ziger S.1, Tung L.1 1GeneCure Biotechnologies, Norcross, GA, United States
TUPEA069 Abstract	Promoter targeted siRNAs induce gene silencing of simian immunodeficiency virus (SIV) infection in vitro Presented by Heidi Gaik Wee Lim, Australia (TBC) Lim H.G.W.1, Suzuki K.1, Cooper D.2, Kelleher A.2 1Centre for Immunology, Immunovirology Laboratory, Sydney, Australia, 2National Centre in HIV Epidemiology and Clinical Reaserch, UNSW, Sydney, Australia
TUPEA054 Abstract	Protective role of DC-SIGNR 5/5 neck region repeat polymorphism in HIV-1 exposed seronegative and presence of four conserved DC-SIGN intronic mutation in North Indian individuals Presented by ANURAG RATHORE, India (TBC) Rathore A.1, Dhole T.N.1, Sood V.2, Banerjea A.C.2 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Microbiology, Lucknow, India, 2National Institute of Immunology, New Delhi, India
TUPEB013 Abstract	Quantifying the health benefits of improved diagnostics for pediatric HIV/AIDS Presented by Julia E. Aledort, United States (TBC) Aledort J.E.1, Ronald A.2, LeBlancq S.M.3, Ridzon R.4, Landay A.5, Rafael M.E.1, Shea M.V.1, Safrit J.6, Peeling R.W.7, Hellmann N.4, Mwaba P.8, Holmes K.9, Wilfert C.6 1RAND Corporation, Santa Monica, United States, 2National Coordinating Center for Infectious Diseases, Winnipeg, Canada, 3Columbia University Mailman School of Public Health, Environmental Health Sciences, New York City, United States, 4Bill & Melinda Gates Foundation, Seattle, United States, 5Rush Presbyterian-St. Luke's Medical Center, Chicago, United States, 6Elizabeth Glaser Pediatric AIDS Foundation, Santa Monica, United States, 7World Health Organization, Geneva, Switzerland, 8University of Zambia, School of Medicine, Lusaka, Zambia, 9University of Washington Harborview Medical Center, Center for AIDS and STDs, Seattle, United States
TUPEA047 Abstract	Quinolinic acid induces blood brain barrier disruption: implications for AIDS dementia complex pathogenesis Presented by Robert Owe-Young, Australia (TBC) Owe-Young R.1, Mukhtar M.2, Pomerantz R.3, Walker D.4, Smythe G.5, Armati P.6, Brew B.7 1St. Vincent's Hospital, Centre for Immunology, Darlinghurst, Australia, 2Division of Infectious Diseases, Dept. of Medicine, Thomas Jefferson University, Center for Human Retrovirology, Philadelphia PA, United States, 3Division of Infectious Diseases, Dept. of Medicine, Thomas Jefferson University, Centre for Human Retrovirology, Philadelphia PA, United States, 4Monash University, Dept. of Physiology, Clayton VIC, Australia, 5Faculty of Medicine, University of New South Wales, Biomedical Mass Spectrometry Facility, Kensington NSW, Australia, 6Faculty of Medicine, University of Sydney, Nerve Research Foundation, Sydney NSW, Australia, 7St. Vincent's Hospital, Depts of Neurology & HIV Medicine, Darlinghurst NSW, Australia
TUPEA053 Abstract	RANTES -28G delays and DC-SIGN -139C enhances AIDS progression in HIV-1-infected Japanese hemophiliacs Presented by Hiroshi Ichimura, Japan (TBC) Ichimura H.1, Koizumi Y.2, Kageyama S.1, Fujiyama Y.2, Shioda T.3 1Kanazawa University Graduate School of Medical Science, Department of Viral Infection and International Health, Kanazawa, Japan, 2Shiga University of Medical Science, Department of Internal Medicine, Seta, Ohtsu, Japan, 3Osaka University Research Institute for Microbial Diseases, Department of Viral Infection, Osaka, Japan
TUPEB054 Abstract	Rapid emergence of primary mutations associated with antiretroviral drug resistance in HIV-infected children under HAART Presented by Moira Vignoles, Argentina (TBC) Vignoles M.1, Barboni G.2, Agosti M.R.3, Quarleri J.1, García M.3, Giraudi V.2, González Ayala S.3, Salomón H.1 1National Reference Center for AIDS, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, 2'Dr. Pedro Elizalde' Children Hospital, Buenos Aires, Argentina, 3'Sor María Ludovica' Children Hospital, Buenos Aires, Argentina
TUPEA046 Abstract	Rare HIV-1 etiology in the cerebrospinal fluid and blood of an HIV-infected non-progressor Presented by Nitin Saksena, Australia Saksena N.1, Wang B.1, Carr J.2, Brew B.3 1Westmead Millennium Institute, Retroviral Genetics, Sydney, Australia, 2, Institute of Medical & Veterinary Science, Infectious Diseases, Adelaide, Australia, 3St. Vincent's Hospital, Neurology, Sydney, Australia
TUPEA001 Abstract	Reconstitution of the HBV-specific T cell responses in HIV-1-HBV co-infected individuals following initiation of anti-HBV therapy Presented by Sunee Sirivichayakul, Thailand (TBC) Chang J.J.1, Sirivichayakul S.2, Thompson A.J.V.3, Buranapraditkun S.2, Avihingsanon A.2, Thantiworasit P.2, Marks P.4, Matthews G.4, Visvanathan K.5, Kent S.J.1, Cameron P.U.6, Sasadeusz J.7, Desmond P.8, Locarnini S.A.3, Dore G.J.4, Ruxrungtham K.2, Lewin S.R.9 1University of Melbourne, Department of Microbiology and Immunology, Melbourne, Australia, 2HIV-NAT and Chulalongkorn University, Department of Medicine, Bangkok, Thailand, 3Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia, 4The University of New South Wales, National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia, 5Royal Melbourne Hospital, Department of Medicine, Melbourne, Australia, 6Monash University, Department of Medicine, Melbourne, Australia, 7Royal Melbourne Hospital, Victorian Infectious Diseases Services, Melbourne, Australia, 8St Vincent’s Hospital, Gastroenterology Unit, Melbourne, Australia, 9Alfred Hospital, Infectious Diseases Unit, Melbourne, Australia
TUPEA039 Abstract	Regional heterogeneity in mucosal T cell phenotype is an important variable in studies of HIV mucosal pathogenesis Presented by Ian McGowan, United States Elliot J.1, Adler A.1, Cho D.1, Johnson E.1, Anton P.1, McGowan I.1 1David Geffen School of Medicine at UCLA, Center for Prevention Research, Los Angeles, United States
TUPEB092 Abstract	Relationship between HIV co-receptor tropism and disease progression in persons with untreated chronic HIV infection Presented by Matthew Goetz, United States (TBC) Goetz M.1, Leduc R.2, Kostman J.3, Labriola A.4, Lie Y.5, Weidler J.5, Coakley E.5, Luskin-Hawk R.6, Long Term Monitoring (LTM) Study, Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA 060) 1VA Greater Los Angeles Healthcare System, Infectious Diseases/Medicine, Los Angeles, United States, 2University of Minnesota, Minneapolis, United States, 3UPHS/Presbyterian Medical Center, Philadelphia, United States, 4VA Washington Medical Center, Washington, United States, 5Monogram Biosciences, South San Francisco, United States, 6Saint Joseph Hospital, Chicago, United States
TUPEA004 Abstract	Reporting ongoing internal peripheral blood mononuclear cell (PBMC) cryopreservation quality control Presented by Julie Yeung, Australia (TBC) Yeung J.1, Merlin K.1, Munier M.L.2, McGinley C.3, Kelleher A.2 1HIV Immunovirology Research Laboratory, St Vincent's and Mater Health Research Campus, Sydney, Australia, 2HIV Immunovirology Research Laboratory, St Vincent's and Mater Health Research Campus; National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia, 3HIV Immunovirology Research Laboratory, National Centre in HIV Epidemiology and Clinical Research, Universtiy of New South Wales, Sydney, Australia
TUPEB053 Abstract	Resistance in ART-naïve paediatric subjects with chronic HIV-1 infection: experiences from a pilot study Presented by Gurpreet Kindra, South Africa (TBC) Bobat R.1, Kiepiela P.2, Kindra G.1, Reddy S.2, Esterhuizen T.3, Pillay V.4, Jeena P.1, Adhikari M.1, Coovadia H.1, Morris L.4 1University of KwazuluNatal,Nelson R Mandela School of Medicine, Durban, South Africa, Department of Paediatrics and Child health, Durban, South Africa, 2University of KwazuluNatal,Nelson R Mandela School of Medicine, Durban, South Africa, HPP Laboratory, Department of Paediatrics and Child health, Durban, South Africa, 3University of KwazuluNatal,Nelson R Mandela School of Medicine, Durban, South Africa, Biostatistics, Durban, South Africa, 4National Institute for Communicable Diseases, AIDS Virus Research Unit, Johannesburg, South Africa
TUPEB055 Abstract	Resistance to antiretroviral therapy in pediatrics HIV/AIDS Chilean patients, 2002-2005 Presented by WILLIAM ACEVEDO, Chile (TBC) Acevedo W.1, Alvarez A.2, Hernández M.3, Comité Nacional de SIDA pediátrico 1Hospital Clinico Universidad de Chile, Medicina Interna - Inmunologia, Santiago, Chile, 2Hospital San Juan de Dios, Pediatria, Santiago, Chile, 3Hospital Clinico Universidad de Chile, Facultad de Medicina, Santiago, Chile
TUPEB130 Abstract	Response to HAART in naïve HIV-1 infected children in Argentina Presented by Debora Mecikovsky, Argentina (TBC) Mecikovsky D.1, Blumetti V.1, Bologna R.1, Rocco C.1, Mangano A.1, Sen L.1 1Hospital de Pediatría J.P.Garrahan, Infectology, Buenos Aires, Argentina
TUPEB115 Abstract	Risk factors for postpartum complications among HIV-infected women in Rio de Janeiro, Brazil Presented by Esau Joao, Brazil Calvet G.1, Joao E.1, Cunha C.1, Silva R.1, Sidi L.1, Silva S.1, Medeiros A.1, Martins E.1, Menezes J.1 1Hospital dos Servidores do Estado, Infectious Diseases Department, Rio de Janeiro, Brazil
TUPEC018 Abstract	Routine counselling for HIV testing among STI clinic attendees: pilot study at University Teaching Hospital, Lusaka, Zambia Presented by CHARLES FOUNTAIN LUHANA, Zambia (TBC) Luhana C.F.1, Yassa P.2, Malibata C.2, Macuacua R.2, Kangwa L.2, Matembo T.3, Kimbinyi W.4, Mwila J.K.5, Chama G.C.5 1Maina Soko Hospital, Dermato-Venereology;, Defence Force Medical Services, Lusaka, Zambia, 2University Teaching Hospital, Dermato-Venereology Dept, Lusaka, Zambia, 3RDTC at KCMC, Moshi, Tanzania, United Republic of, 4Ministry of Education, Lusaka, Zambia, 5Lusaka District Management Team, Lusaka, Zambia
TUPEB107 Abstract	Safety and efficacy of a replacement feeding program in prevention of mother to child transmission (PMTCT) of HIV in resource limited setting: the experience Maragua District, CentralProvince, Kenya Presented by George Nzioka, Kenya Mugo P.1, Rumunyu M.1, Nzioka G.1, Torres V.1, Kamande M.1, Githinji J.1, Gitahi J.1, Mwangi L.1, Thegeya E.1 1Maragua District Hospital, Maragua, Kenya
TUPEC037 Abstract	Scaling up prevention of mother to child transmission (PMTCT) using parental knowledge to reinforce PMTCT strategies Presented by Twaha Sendagi, Uganda (TBC) Sendagi T.1, Omongin P.2, Nsobya G.3 1Positive Men's Union (POMU), Kampala, Uganda, 2Social Worker, Kampala, Uganda, 3Community Health Worker, Kampala, Uganda
TUPEA068 Abstract	Seminal plasma HIV-1 load: effect of ART and sexually transmissible infections Presented by Derek Chan, Australia (TBC) Chan D.1, Smith D.1, McNally L.2, Cunningham P.3, Batterham M.4 1Albion Street Centre, Prince of Wales Hospital, Sydney, Australia, 2SydPath, St Vincent's Hospital, Sydney, Australia, 3Centre for Immunology, St Vincent's Hospital, Sydney, Australia, 4University of Wollongong, School of Health Sciences, Sydney, Australia
TUPEC021 Abstract	Sex workers and sexually transmitted diseases: are prevention practices routinely adopted? Presented by Ana Maria Ferreira Borges Teixeira, Brazil (TBC) Teixeira A.M.F.B.1, Freitas da Silveira M.1, Antunes Brum V.M.1, Alves C.L.1 1Universidade Federal de Pelotas, Department of Social Medicine, Pelotas, Brazil
TUPEC007 Abstract	Sexual habits and dilemma of vaginal microbicide as an HIV preventive measure Presented by Orikomaba Obunge, Nigeria (TBC) Obunge O.1, Onyejepu N.2 1University of Port Harcourt Teaching Hospital, Medical Microbiology, Port Harcourt, Nigeria, 2Nigerian Institute of Medical Research, Medical Microbiology, Lagos, Nigeria
TUPEA021 Abstract	Similar distribution of HIV-specific functional subsets to responses directed against epitopes restricted by HLA-B*27 and B*57 in long term non progressors and progressors Presented by Yoav Peretz, Canada (TBC) Peretz Y.1, Marra O.2, Simic N.1, Tremblay C.3, Bernard N.F.1 1McGill University Health Center, Medicine, Montreal, Canada, 2McGill University, Montreal, Canada, 3Centre de Recherche du Centre Hospitalier de l'Université de Montreal, Montreal, Canada
TUPEA063 Abstract	SIV infects the male reproductive organs of non-human primates during primary and chronic stages Presented by Nathalie Dejucq-Rainsford, France (TBC) Le Tortorec A.1, Denis H.1, Satie A.-P.1, Roques P.2, Jégou B.1, Le Grand R.2, Dejucq-Rainsford N.1 1GERHM-Inserm U625, Rennes, France, 2CEA, Service de Neurovirologie, Fontenay-aux-roses, France
TUPEA035 Abstract	Soluble immune markers in individuals treated for 6 years with a lopinavir/ritonavir (LPV/r)-based antiretroviral (ARV) regimen Presented by Alan Landay, United States (TBC) Landay A.1, King M.2, Tschampa J.3, French M.A.H.4, da Silva B.A.5 1Rush University Medical Center, Immunology/Microbiology, Chicago, United States, 2Abbott Laboratories, Statistics, Abbott Park, United States, 3Abbott Laboratories, Antiviral Team, Abbott Park, United States, 4University of Western Australia, Dept of Clinical Immunology, Perth, Australia, 5Abbott Laboratories, Antiviral Clinical Team, Abbott Park, United States
TUPEB083 Abstract	Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy Presented by Jesper Eugen-Olsen, Denmark (TBC) Andersen O.1, Eugen-Olsen J.1, Kofoed K.1, Stausgaard A.1, Iversen J.2, Haugaard S.B.1 1Copenhagen University Hospital Hvidovre, Clinical Research Unit 136, Hvidovre, Denmark, 2Copenhagen University Hospital Hvidovre, Dept. of Infectious Diseases, Hvidovre, Denmark
TUPEA019 Abstract	Strong ability of HLA-C*1202-restricted cytotoxic T lymphocytes to suppress HIV-1 replication Presented by Kazutaka Honda, Japan (TBC) Honda K.1, Koizumi H.1, Dohki S.1, Kitano M.1, Iwatani T.1, Oka S.2, Takiguchi M.1 1Kumamoto University, Center for AIDS Resarch, Kumamoto, Japan, 2International Medical Center of Japan, AIDS Clinical Center, Tokyo, Japan
TUPEB062 Abstract	Study of cardiovascular risk evaluation by Framingham Risk score and sestimibi exercise stress testing in HIV/AIDS compared to non-HIV-infected individuals (stress) Presented by GARY BLICK, United States (TBC) Blick G.1, Greiger-Zanlungo P.2, Plasencia V.1, Ulrich G.1, Gretz S.1, Heiman M.3, Alaie D.4, Dupree D.2, Garton T.1, Luke D.5 1Circle Medical LLC, Norwalk, United States, 2Mt. Vernon Hospital, Dept. of Medicine, Mt. Vernon, United States, 3Columbia-New York Presbyterian Hosp/Stamford Hospital, Dept. of Cardiology, Stamford, United States, 4Mt. Vernon Hospital, Dept. of Cardiology, Mt. Vernon, United States, 5Pfizer, Inc., New York, United States
TUPEB063 Abstract	Subclinical coronary atherosclerosis, HIV-infection and antiretroviral therapy: results from the Multicenter AIDS Cohort Study Presented by Lawrence Kingsley, United States (TBC) Kingsley L.1, Cuervo J.2, Munoz A.2, Palella F.3, Budoff M.4, Post W.5, Witt M.6, Kuller L.7 1University of Pittsburgh, Graduate School of Public Health, Infectious Diseases and Epidemiology, Pittsburgh, United States, 2Johns Hopkins Bloomberg School of Public Health, Epidemiology, Baltimore, United States, 3Northwestern University, Medicine, Chicago, United States, 4Harbor-UCLA Medical Center, Medicine, Torrance, United States, 5Johns Hopkins School of Medicine, Medicine, Baltimore, United States, 6University of California, David Geffen School of Medicine and the Los Angeles Biomedical Research Institute at Harbor-UCLA, Medicine, Los Angeles, United States, 7University of Pittsburgh, Graduate School of Public Health, Epidemiology, Pittsburgh, United States
TUPEB133 Abstract	Substitution of stavudine with zidovudine in HIV-infected children receiving HAART does NOT result in clinically significant hematologic changes Presented by Linda Aurpibul, Thailand (TBC) Aurpibul L.1, Puthanakit T.1, Sirisanthana T.1, Sirisanthana V.2 1Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand, 2Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
TUPEA032 Abstract	Successful HAART is associated with high β-chemokines levels in chronic HIV-1-infected patients Presented by Adriana Brito, Brazil (TBC) Brito A.1, Almeida A.1, Gonsalez C.1, Mendonça M.1, Ferreira F.1, Fernandes S.S.1, Duarte A.J.S.1, Casseb J.1 1Medicine School of Sao Paulo University, Laboratory of Immunology and Dermatology, Sao Paulo, Brazil
TUPEA074 Abstract	Successful immunization with a single injection of nonintegrating lentiviral vector Presented by Andrea Cara, Italy (TBC) Negri D.R.M.1, Michelini Z.1, Baroncelli S.1, Spada M.1, Vendetti S.1, Bona R.1, Leone P.1, Buffa V.2, Klotman M.E.3, Cara A.1 1Istituto Superiore di Sanità, Rome, Italy, 2St. George’s University of London, London, United Kingdom, 3Mount Sinai School of Medicine, New York, United States
TUPEB009 Abstract	Targeted rapid HIV testing in an urban hospital: implications for prevention and treatment interventions Presented by Debbie Mohammed, United States (TBC) Mohammed D.1, Fleming P.1, Jaker M.1, Hodder S.1, Paul S.2 1UMDNJ, New Jersey Medical School, Newark, United States, 2Department of Health and Senior Services, Division of HIV/AIDS Services, Trenton, United States
TUPEA065 Abstract	Targeting the persistent HIV reservoir by combined cis- and trans-activators Presented by Dean Hamer, United States (TBC) Hamer D.1, Wang T.1 1NIH/NCI, Vaccine Branch, Bethesda, United States
TUPEA066 Abstract	The alarmin High-Mobility Group Box 1 (HMGB1) protein induces HIV-1 expression from persistently infected cells Presented by joel gozlan, France (TBC) Gozlan J.1, Thierry S.1, Boniface R.1, Strauss F.1, Marechal V.1 1Centre de Recherche des Cordeliers, UMR 7079, Paris, France
TUPEA023 Abstract	The association of HIV-specific T cell responses and drug-resistance in chronic paediatric infection before and during antiretroviral therapy (continuous and structured treatment interruption) Presented by Shabashini Reddy, South Africa (TBC) Reddy S.1, HPP Study Group 1HPP- University of Kwa-Zulu Natal, Child Health and Maternal Care, Pinetown, South Africa
TUPEB143 Abstract	The challenge of disclosure in resource-limited setting: experience in Ugandan HIV-infected children Presented by Maria Nannyonga-Musoke, Uganda (TBC) Nannyonga-Musoke M.1, Penazzato M.2, Morelli E.2, Mayanja S.P.1, Ingabire R.1, Mazza A.3, Giaquinto C.2 1St.Raphael of St.Francis Nsambya Hospital, Home Care, Kampala, Uganda, 2Department of Pediatrics, Padova, Italy, 3Santa Chiara Hospital, Trento, Italy
TUPEB082 Abstract	The effect of antiretroviral therapy on genes involved with lipid metabolism and mitochondrial function Presented by Mohsen Shahmanesh, United Kingdom Boothby M.1, Tomlinson J.W.2, McGee K.C.3, Das S.4, Gathercole L.L.2, Harte A.L.3, Higgins P.3, Kusminski C.M.3, McTernan P.G.3, Shahmanesh M.1 1University Hospital Birmingham, HIV Medicine, Birmingham, United Kingdom, 2University of Birmingham, Division of Medical Sciences, Birmingham, United Kingdom, 3Warwick University, Clinical Science Research Institute, Warwick, United Kingdom, 4Walsgrave Hospital, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom
TUPEC038 Abstract	The effect of ARVs on ARV naive HIV/AIDS patients treated in paediatric infectious disease clinics in Moshi town Presented by Aisa Shayo, Tanzania, United Republic of (TBC) Shayo A.1 1Kilimanjaro Christian Medical Centre, Paediatrics, Kilimanjaro, Tanzania, United Republic of
TUPEB043 Abstract	The effect of canonical resistance mutations in naïve HIV-1 infected patients on the proportion achieving virological success when starting NNRTI-based and PI-based regimens Presented by Sundhiya Mandalia, United Kingdom Price H.1, Jones R.1, Mandalia S.1, Bower M.1, Nelson M.1, Gazzard B.1 1Chelsea & Westminster Hospital, Department of HIV Medicine, London, United Kingdom
TUPEB059 Abstract	The impact of HIV 1 viral diversity on viral load quantification Presented by M. John Gill, Canada (TBC) Gill M.J.1, Beckthold B.1, Church D.2, Kim J.3 1Southern Alberta Clinic, Calgary, Canada, 2Calgary Laboratory Services, Calgary, Canada, 3Chief National Reference Lab, Ottawa, Canada
TUPEB140 Abstract	The measurement of pediatric adherence to antiretroviral therapy: a systematic review Presented by Rachel Vreeman, United States (TBC) Vreeman R.1, Wiehe S.1, Nyandiko Mokoya W.2 1Children's Health Services Research, Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States, 2School of Medicine, Moi University, Child Health and Paediatrics, Eldoret, Kenya
TUPEC005 Abstract	The microbicide field response to clinical trial challenges Presented by Latifa Boyce, United States (TBC) Boyce L.1, Plescia C.1, Finley B.1, Harrison P.1, des Vignes F.1 1Alliance for Microbicide Development, Silver Spring, United States
TUPEA057 Abstract	The Nef-PAK2 connection in HIV and SIV – what’s the difference? Presented by Kevin K. Ariën, Belgium (TBC) Ariën K.K.1, Naessens E.1, Stove V.1, Verhofstede C.1, Schindler M.2, Fackler O.T.3, Kirchhoff F.2, Verhasselt B.1 1Ghent University, Department of Clinical Chemistry, Microbiology, and Immunology, Faculty of Medicine and Health Sciences, Ghent, Belgium, 2University of Ulm, Institute of Virology, Ulm, Germany, 3University of Heidelberg, Department of Virology, Heidelberg, Germany
TUPEB029 Abstract	The prevalence of resistant mutations to enfuvirtide in antiretroviral naive HIV-1 infected patients Presented by Choo Beng Chew, Australia (TBC) Chew C.B.1, Shah M.2, Wang B.2, Shaw C.O.1, Ng K.P.3, Kamarulzaman A.4, Saksena N.K.2, Dwyer D.E.1 1Westmead Hospital, CIDMLS, Westmead, Australia, 2Westmead Hospital, CVR, Westmead, Australia, 3University of Malaya, Medical Microbiology, Kuala Lumpur, Malaysia, 4University Hospital, Infectious Diseases, Kuala Lumpur, Malaysia
TUPEB050 Abstract	The prevalence of transmitted HIV-1 drug resistance in recently HIV-1 infected injecting drug users in Bangkok, Thailand 2001-2004 Presented by Wannee Chonwattana, Thailand (TBC) Chonwattana W.1, Leelawiwat W.1, Kittinunvorakoon C.1, Choopanya K.2, Vanichseni S.2, Martin M.T.1, van Griensven F.1, Fox K.1, Tappero J.W.3, Gurwith M.4, McNicholl J.M.1 1Thailand MOPH - U.S. CDC Collaboration, Nonthaburi, Thailand, 2Bangkok Vaccine Evaluation Group, Bangkok, Thailand, 3Centers for Disease Control and Prevention, Atlanta, GA, United States, 4VaxGen Inc., Brisbane, CA, United States
TUPEB078 Abstract	The rate at which therapy naïve patients develop metabolic syndrome when treated and its association with different components of antiretroviral therapy in the Swiss HIV Cohort Study Presented by Heiner C. Bucher, Switzerland (TBC) Young J.1, Glass T.1, Weber R.2, Bernasconi E.3, Rickenbach M.4, Furrer H.5, Cavassini M.6, Vernazza P.7, Hirschel B.8, Battegay M.9, Bucher H.C.1, and the Swiss HIV Cohort Study 1Basel Institute for Clinical Epidemiology, University Hospital Basel, Basel, Switzerland, 2Division of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland, 3Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland, 4Swiss HIV Cohort Data Center, University of Lausanne, Lausanne, Switzerland, 5Division of Infectious Diseases, Insel Spital, Berne, Switzerland, 6Division of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland, 7Division of Infectious Diseases, Cantonal Hospital St. Gall, St. Gallen, Switzerland, 8Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland, 9Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland
TUPEB096 Abstract	The role of cigarette smoking on HIV/AIDS mortality Presented by Lien A Quach, United States (TBC) Quach L.A.1, Tang A.M.1, Schmid C.H.2, Gorbach S.L.1, Wanke C.1 1Tufts University School of Medicine, Public Health and Family Medicine, Boston, United States, 2Tufts University, Biostatistics Research Center, Boston, United States
TUPEA012 Abstract	The role of HIV-induced maturation of dendritic cells in HIV immunopathogenesis Presented by Sarah Kate Mercier, Australia (TBC) Mercier S.K.1, Harman A.N.1, Donaghy H.1, Cunningham A.L.1 1Westmead Millennium Institute, CVR, Westmead, Australia
TUPEA050 Abstract	The role of S-100β in the pathogenesis of HIV associated dementia (HAD) Presented by Louise Pemberton, Australia (TBC) Pemberton L.1, Kate T.2, Gorry P.2, Steve W.3, Brew B.4 1Centre for Immunology, St. Vincent's Hospital, Neurovirology, Sydney, Australia, 2Macfarlane Burnet Institute for Medical Research & Public Health, HIV Molecular Pathogenesis Laboratory, Melbourne, Australia, 3Macfarlane Burnet Institute for Medical Research & Public Health, Deparent of Infectious Diseases, Melbourne, Australia, 4St Vincent's Hospital, Department of Neurology, Sydney, Australia
TUPEA070 Abstract	The use of carbosilane dendrimers to improve the effectivity of siRNA as a treatment for HIV infection Presented by Nicholas Weber, Spain (TBC) Weber N.1, Ortega P.2, de la Mata F.J.2, Gómez R.2, Muñoz-Fernández M.A.1 1Hospital General Universitario Gregorio Marañón, Laboratorio Inmunobiología Molecular, Madrid, Spain, 2Universidad de Alcalá de Henares, Química Inorganica, Alcalá de Henares, Spain
TUPEB126 Abstract	Therapeutic drug monitoring of lopinavir / ritonavir in HIV infected children Presented by Veronica Curras, Argentina (TBC) Curras V.1, Hocht C.1, Cacers Guido P.2, Mato G.2, Mecikovsky D.3, Bologna R.3, Rubio M.1, Bramuglia G.1 1Facultad de Farmacia y Bioquimica Universidad de Buenos Aires, Catedra de Farmacologia, Buenos Aires, Argentina, 2Hospital de Pediatria Garrahan, Area de Farmacia, Buenos Aires, Argentina, 3Hospital de Pediatria Garrahan, Servicio de Control Epidemiológico e Infectologia, Buenos Aires, Argentina
TUPEB005 Abstract	Time trend analysis of sociodemographic characteristics and HIV risk factors of clients presenting for VCT in Moshi, Tanzania from 2003-2006 Presented by Meghan Mayhood, United States (TBC) Mayhood M.1, Ostermann J.2, Crump J.3, Tribble A.1, Itemba D.4, Mgonja A.4, Mtalo A.4, Mtweve S.3, Bartlett J.1, Shao J.3, Thielman N.1, Kilimanjaro Christian Medical Centre-Duke University AIDS Program 1Duke University Medical Center, Durham, United States, 2Center for Health Policy, Duke University, Durham, United States, 3Kilimanjaro Christian Medical Centre, Moshi, Tanzania, United Republic of, 4KIWAKKUKI (Women Against AIDS in Kilimanjaro), Moshi, Tanzania, United Republic of
TUPEA020 Abstract	Under pressure! Kinetics of SIV Gag-specific CD8+ T cell escape and reversion: implications for immune control of HIV Presented by Liyen Loh, Australia (TBC) Loh L.1, Fernandez C.1, Reece J.1, Smith M.1, Batten J.1, De Rose R.1, Petravic J.2, Davenport M.2, Kent S.1 1University of Melbourne, Microbiology and Immunology, Melbourne, Australia, 2University of New South Wales, Center for Vascular Research, Sydney, Australia
TUPEB081 Abstract	Upregulation of the mitochondrial PRSS15/LON during lipodistrophy: ex vivo and in vitro detection Presented by Marcello Pinti, Italy Pinti M.1, Gibellini L.1, Guaraldi G.2, Orlando G.3, Roat E.1, Mussini C.3, Salomoni P.4, Gant T.4, Cossarizza A.1 1University of Modena and Reggio Emilia, Department of biomedical sciences, Modena, Italy, 2University of Modena and Reggio Emilia, School of Medicine, Infectious Disesase Clinics, Modena, Italy, 3University of Modena and Reggio Emilia- School of Medicine, Infectious Disesase Clinics, Modena, Italy, 4University of Leicester, MRC Toxicology Unit, Leicester, United Kingdom
TUPEB031 Abstract	Usefulness of genotypic resistance tests (GRT) in patients with HIV-1 viral loads (VL) less than 1000 copies/m Presented by Michael Aboud, United Kingdom Tong W.1, Chrystie I.1, Aboud M.2, Oshea S.1, Elgalib A.2, DeReuters A.2, Kulasegaram R.2 1Guy's and St Thomas' Hospitals NHS Trust, Department of Virology, London, United Kingdom, 2Guy's and St Thomas' Hospitals NHS Trust, Harrison Wing, London, United Kingdom
TUPEC023 Abstract	Using research to determine media mix and minimum frequency of exposure to create STI treatment seeking behavior change among male clients of female commercial sex workers in high-prevalence towns in Andhra Pradesh, Karnataka, Maharashtra, and Tamil Nadu, India: the PSI/Avahan example Presented by Risha Hess, India Navin D.1, Hess R.2 1Population Services International, Research, New Delhi, India, 2Population Services International, Communications, New Delhi, India
TUPEA071 Abstract	Utility of the Sindbis replicon system as an Env-targeted HIV vaccine Presented by Rob John Center, Australia Schoenberner A.1, Center R.J.1, Campbell S.M.1, Siebentritt C.1, Purcell D.F.J.1 1University of Melbourne, Department of Microbiology and Immunology, Parkville, Australia
TUPEB023 Abstract	Utilization of HIV RNA tests for infant diagnosis in Brazil, 2000-2006 Presented by Machline Paganella, Brazil (TBC) da Silva de Souza R.1, de Souza D.2, do Amaral Inocêncio L.2, Page-Shafer K.3, Spindler H.4, Paganella M.5, Pilcher C.6 1Universidade de Caxias do Sul, Clinical Medicine, Caxias do Sul, Brazil, 2Programa Nacional de DST/AIDS, Ministério da Saúde, Brasilia, Brazil, 3University of California San Francisco, Center for AIDS Prevention Studies, San Francisco, United States, 4University of California San Francisco, Institute for Global Health, San Francisco, United States, 5Universidade de Caxias do Sul- Laboratório de Pesquisa em HIV/AIDS, Centro de Ciencias Biológicas e da Saúde, Caxias do Sul, Brazil, 6San Francisco General Hospital, HIV/AIDS Division, San Francisco, United States
TUPEB124 Abstract	Validation of clinical algorithms for diagnosis of HIV-1 infection and initiation of antiretroviral therapy in exposed children aged less than 18 months in Kenya Presented by Irene Inwani, Kenya (TBC) Inwani I.1, Ngacha D.-M.2, Nduati R.2, Obimbo E.2, Wamalwa D.2, John-Stewart G.3, Farquhar C.3 1Kenyatta National Referral Hospital, Paediatrics, Nairobi, Kenya, 2University of Nairobi, Paediatrics and Child Health, Nairobi, Kenya, 3School of Public Health, University of Washington, Epidemiology, Seattle, United States
TUPEB104 Abstract	Variable uptake of recommended interventions to reduce perinatal HIV transmission in Australia 1982-2005 Presented by Ann McDonald, Australia Giles M.1, McDonald A.2, Elliott E.3, Ziegler J.4, Hellard M.5, Lewin S.1, Kaldor J.2 1Department of Medicine Monash University and Infectious Diseases Unit Alfred Hospital, Melbourne, Australia, 2National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia, 3University of Sydney and Australian Paediatric Surveillance Unit, Sydney, Australia, 4Sydney Children's Hospital, Sydney, Australia, 5Burnet Institute and Infectious Diseases Unit Alfred Hospital, Melbourne, Australia
TUPEC032 Abstract	Vertical transmission of HIV in mothers from different socio-cultural settings in Northern Nigeria Presented by Atiene Sagay, Nigeria (TBC) Sagay A.1, Kapiga S.2, Imade G.1, Pam S.1, Ekwempu C.1, Oguche S.1, Onotu D.1, Sankale J.-L.2, Idoko J.1, Kanki P.2 1APIN/PEPFAR Project, Jos University Teaching Hospital, Jos, Nigeria, 2Harvard School of Public Health, Boston, United States
TUPEB003 Abstract	Viral dynamics among early seroconverters in an HIV discordant couples cohort in Zambia Presented by Olivier Manigart, Zambia (TBC) Manigart O.1, Stevens G.2, Boeras D.3, Chanda S.4, Krebs M.5, Lakhi S.4, Priddy F.6, Allen S.3, Gilmour J.6, Hunter E.3 1Rwanda Zambia HIV Research Group/Emory University/Atlanta, Virology, Lusaka, Zambia, 2International AIDS Vaccine Initiative (IAVI), Laboratory, Johannesburg, South Africa, 3RZHRG/Emory University, Atlanta, United States, 4RZHRG, Lusaka, Zambia, 5IAVI, Lusaka, Zambia, 6IAVI, New York, United States
TUPEA034 Abstract	Vitamin D3 inhibits X4 but enhance R5 HIV-1 replication in IL-2 stimulated PBMC Presented by Massimo Alfano, Italy (TBC) Alfano M.1, Rizzi C.1, Penna G.2, Adorini L.2, Poli G.1 1Scientific Institute San Raffaele, Immunology and Infectious Diseases Department, Milan, Italy, 2BioXell SpA, Milan, Italy
TUPEB039 Abstract	Which ARV options in Republic of Congo and Burkina-Faso for patients with failure after 4 years of therapy: the French Red Cross experience in the day care centres in Brazzaville, Pointe-Noire and Ouagadougou Presented by Christian Courpotin, France Sibille B.1, Mouala C.2, Fila A.3, Burgard M.4, Nzounza P.1, Zabsonre I.5, Delaugerre C.6, Tran-Minh T.2, Avettand Fenoel V.4, De Truchis P.7, Courpotin C.8, Adam G.2, Mattei J.-F.2 1Centre de Traitement Ambulatoire, Brazzaville, Congo, 2Croix-Rouge française, Paris, France, 3Centre de Traitement Ambulatoire, Pointe-Noire, Congo, 4CHU Necker, EA 3620, Université Paris-Descartes, Paris, France, 5Centre de Traitement Ambulatoire, Ouagadougou, Burkina Faso, 6Hôpital Ambroise Paré, Boulogne Billancourt, France, 7Hôpital Raymond Poincaré, Garches, France, 8Action Plus Sida Santé, Paris, France
TUPEB022 Abstract	Whole blood ELISA for cell-associated CD4 provides a simple method for estimation of CD4+ T cell counts Presented by Robyn Lloyd, Australia (TBC) Lloyd R.1, Diaz J.2, Garcia M.2, Denny T.3, Landay A.4, Crowe S.1, Anderson D.5 1Burnet Institute, AIDS Pathogenesis and Clinical Research Program, Melbourne, Australia, 2Burnet Institute, AIDS Pathogenesis and Clinical Research & Molecular Virology Programs, Melbourne, Australia, 3Duke University School of Medicine, Duke Human Vaccine Institute, Durham, United States, 4Rush University Medical Center, Department of Immunology and Microbiology, Illinois, United States, 5Burnet Institute, Molecular Virology Program, Melbourne, Australia
TUPEB001 Abstract	Wide diversity of early virological and immunological markers and correlation with clinical symptoms in patients diagnosed at the time of primary HIV infection and enrolled in the ANRS primo cohort Presented by Jade Ghosn, France (TBC) Ghosn J.1, Deveau C.2, Goujard C.1, Pellegrin I.3, Galimand J.4, Tamalet C.5, Souhala F.6, Nau P.7, Loison J.8, Cheret A.9, Meyer L.2, Rouzioux C.4, Chaix M.-L.4, PRIMO Cohort ANRS Co 06 1Bicetre Hospital, Internal Medicine and Infectious Diseases Department, Kremlin-Bicetre, France, 2Bicêtre Hospital, Epidemiology, Demography and Social Sciences, INSERM U822, National Institute of Health and Medical Research, University Paris 11, Kremlin-Bicetre, France, 3Pellegrin Hospital, Virology Department, Bordeaux, France, 4Necker Hospital, Virology Department, René Descartes Paris 5 University, EA MRT 3620, Paris, France, 5La Timone Hospital, Virolgy Department, Marseille, France, 6Pontchaillou Hospital, Infectious Diseases Department, Rennes, France, 7Bretonneau Hospital, Infectious Diseases Department, Rennes, France, 8Centre Hospitalier Regional, Infectious Diseases Department, Angers, France, 9Chalucet Hospital, Department of Internal Medicine and Haematology, Toulon, France
TUPEC003 Abstract	Willingness to participate in trials of rectal microbicides among HIV-negative gay men in Sydney Presented by Garrett Prestage, Australia (TBC) Prestage G.1, Poynten M.1, Jin F.1, Imrie J.2, Kippax S.2, Donovan B.1, Kaldor J.1, Grulich A.1 1National Centre in HIV Epidem and Clin Research, Darlinghurst, Australia, 2National Centre in HIV Social Research, Sydney, Australia
TUPEC004 Abstract	Women’s agency in sexual negotiation and HIV prevention in Mwanza, Tanzania: considerations for the acceptability of vaginal microbicides Presented by Andrew Vallely, Tanzania, United Republic of Lees S.1, Desmond N.2, Allen C.3, Bugeke G.4, Vallely A.5, Hayes R.1, Ross D.1, Microbicides Development Programme 1London School of Hygiene and Tropical Medicine, IDEU, London, United Kingdom, 2Medical Research Council, Glasgow, United Kingdom, 3Caribbean Health Research Council, St. Augustine, Trinidad and Tobago, 4National Institute of Medical Research, Mwanza, Tanzania, United Republic of, 5University of Queensland, Queensland, Australia